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Abstract 
 
       Using an in situ intestinal perfusion model in sow-fed neonatal piglets, our objectives were to 
determine whether the lysyl-lysine enhanced arginine absorption led to a functional benefit of 
greater mucosal protein synthesis, and whether it was mediated through the mTOR pathway. Three 
segments of piglet’s small intestine were isolated, and were continuously perfused with: arginine, 
arginine + lysyl-lysine, or arginine + L-lysine. At 90 min, buffers containing the same amino acids 
plus phenylalanine were initiated for 30 min to measure mucosal protein synthesis. Six additional 
piglets underwent the identical protocol, but one hour before the intestinal perfusion, rapamycin 
was delivered intravenously. Co-perfusing arginine with lysyl-lysine resulted in greater arginine 
uptake, and higher mucosal protein synthesis. Moreover, both protein synthesis and the 
phosphorylation of mTOR were inhibited by rapamycin. Thus, lysyl-lysine led to a greater mucosal 
protein synthesis, which was likely mediated through enhanced arginine absorption. 
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Chapter 1:  Literature Review. 
 
1.1 Arginine. 
 
1.1.1. Arginine nutrition. 
       In the body, arginine is derived from protein turnover, diet, and de novo synthesis (Morris, 
2006). Arginine has many important metabolic roles other than as a component of proteins; 
arginine serves as a precursor for important metabolites such as nitric oxide (NO), a molecule that 
regulates vascular relaxation and influences the immune response, polyamines which are important 
for cellular growth, and creatine which is involved in cellular energy metabolism (Wu & Morris, 
1998; Wyss & Kaddurah-Daouk, 2000).  Arginine is also an intermediate in the urea cycle, and is 
necessary for the disposal of ammonia through the production of urea (Wu & Morris, 1998).  In 
neonates, arginine is a conditionally essential amino acid, as a dietary source is required for optimal 
growth (Wu, Knabe, & Kim, 2004). Arginine is also conditionally essential in adults; however, 
the need for a supplement is linked to the individual’s health (Jacobs ,2011).  
 
1.1.2. De novo arginine synthesis. 
       The organs involved in de novo arginine synthesis change in relative importance with 
development (Wu, Jaeger, Bazer & Rhoads, 2004 a). During early neonatal life, the small intestine 
is responsible for the synthesis of arginine. Amino acid precursors, predominantly proline, are 
converted into ornithine and citrulline and then to arginine (Bertolo, Brunton, Pencharz & Ball, 
2003). A previous study demonstrated that ornithine aminotransferase (OAT) and proline 
dehydrogenase were both expressed in the neonatal piglet small intestine which facilitated the 
conversion of proline to arginine through ornithine (Bertolo et al., 2003). Also, negligible 
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expression of arginase in the small intestine resulted in the release of newly synthesized arginine 
into the portal blood (Bertolo et al., 2003). This intestinal metabolism is tremendously important 
for normal arginine homeostasis because most other organs, including the kidney, are not capable 
of producing sufficient arginine to meet the whole body needs (Cynober, Boucher& Vasson, 
1995). As a result, arginine synthesis in enterocytes is essential and it compensates for the low 
arginine concentration in mammary milk (Wu, Knabe & Kim, 2004 b). 
 
In piglets, it has been demonstrated that as the animal ages, arginine synthesis is reduced in 
enterocytes due to an increase in the expression of arginase (Blachier, M'rabet-­‐touil, Posho, Darcy-­‐
Vrillon & Duée, 1993). This change affects the ability of enterocytes to synthesize and release 
arginine; instead, the amino acid precursors are converted to, and released as citrulline (Cynober 
et al., 1995). The direct precursor of citrulline in the small intestine is ornithine, which is 
synthesized in enterocytes from glutamine and proline (Marini, Stoll, Didelija & Burrin, 2012). 
The citrulline is released into the portal blood, and is taken up by the kidneys, where it is converted 
into argininosuccinate and then arginine in the proximal tubules (Jacobs, 2011; Morris, 2006).  
 
In the liver, arginine is also produced in the urea cycle; however, due to the high cytosolic arginase 
activity, most of the newly formed arginine is hydrolyzed to release urea and ornithine (Flynn, 
Meininger, Haynes & Wu, 2002). As a result, the predominant source of endogenously synthesized 
arginine is the intestine in early life (Bertolo et al., 2003). After weaning, citrulline is released 
from the gut and arginine is formed by the intestinal-renal axis (Cynober et al., 1995; Windmueller 
& Spaeth, 1981). 
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1.1.3. Advantages of supplementing arginine to neonates.  
       The arginine concentration in mammal’s milk, such as pigs, humans and cows, is considerably 
low, and is estimated in pigs to supply only 40% of the required arginine at one week of age 
(Jacobs, 2011; Wu et al., 2007).  As a result, in young milk-fed animals, growth may be limited, 
particularly if de novo synthesis is impaired for some reason (Wu et al., 2007). Supplementing 
arginine in the diet of early weaned pigs for two weeks, at concentrations of 0.2% and 0.4% 
improved the daily weight gain by 28% and 66%, respectively, resulting in final body weights that 
were 15% and 32% greater than controls. These results suggest that the arginine content in sow 
milk is too low to maximize growth and that supplementing arginine may be beneficial for 
commercial swine production purposes (Kim, McPherson & Wu, 2004).  
 
Weaning in piglets is a stressful event which can negatively affect food intake and growth. 
Weaning also affects gut morphology resulting in reduced nutrient absorption and transport (Lallès 
et al., 2004). Yao et al. (2011) conducted a study that supplemented weaned piglets with 0 or 1% 
arginine added to a basal maize and soybean meal diet. After only 7 days, the daily weight gain 
was 38% greater in the 1% arginine group, and the small intestine’s relative weight was 33% higher 
compared to 0% arginine group. Furthermore, 1% arginine increased both the villus height, and 
the expression of the vascular endothelial growth factor along the entire length of the small 
intestine. Hence, supplementing arginine to the diet may be a beneficial practice during stress 
events in piglets such as gastrointestinal infections or weaning (Yao et al., 2011). Additionally, 
arginine has a role in activating the mTOR signaling pathway which contributes towards 
promoting neonatal growth (Yao et al., 2008). In a separate study by Yao and colleagues (2008), 
piglets were fed sow milk replacer supplemented with arginine at 6% between the age of 7 and 14 
days. They reported enhanced daily body weight gain and the skeletal muscle protein synthesis 
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with the arginine supplement (Yao et al., 2008). 
 
1.1.4. The role of the gastrointestinal tract in arginine deficiency. 
       Many factors may contribute to arginine deficiency in the neonate.  The most common factors 
in human infants include a reduced metabolic mass of intestinal tissue such as gut atrophy due to 
prolonged parenteral feeding, acute intestinal failure due to congenital malformations or infections. 
More rare causes include genetic anomalies such inborn errors of metabolism (e.g. pyrroline-5-
carboxylate synthase (P5CS) deficiency), or transporter defects (Baumgartner et al., 2000; Kamada 
et al., 2001; Piton, Manzon, Cypriani, Carbonnel & Capellier, 2011). 
 
Gut atrophy as the result of prolonged parenteral nutrition (PN) use in preterm infants may be 
common.  PN is used in a high proportion of preterm infants, and is necessary when normal feeding 
into the gastrointestinal tract (GIT) is contraindicated (Hay, 2008). Gut atrophy occurs due to a 
lack of enteral stimulation such as nutrients in the intestinal lumen which may affect anabolic 
hormones. The alteration in these hormones results in gut atrophy which affects the small intestinal 
metabolic capacity, and protein turnover (Bertolo, Chen, Pencharz & Ball, 1999). Gut atrophy that 
is caused by parenteral feeding may disrupt whole body nitrogen metabolism; delivering diet 
through parenteral nutrition to neonatal piglets resulted in the reduction of nitrogen retention 
(Bertolo et al., 1999). According to Bertolo and colleagues (1999), in piglets that were supported 
by a parenteral diet, the weight of the total small intestine and the mucosal mass were reduced by 
40%; intravenously-fed piglets also demonstrated atrophied villous heights with decreased crypt 
depth compared to intragastrically-fed piglets.  This in turn, may have impaired arginine synthesis 
which negatively influenced protein deposition (Bertolo et al., 1999). 
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Indeed, in neonates the gastrointestinal tract has an important role in arginine metabolism, and 
several common factors including PN feeding or severe GI infection such as necrotizing 
enterocolitis may affect the function of the gastrointestinal tract, resulting in arginine deficiency. 
 
1.2. mTOR pathway activation. 
1.2.1. mTOR structure.   
       The mammalian or mechanistic target of rapamycin (mTOR), which is a serine/ threonine 
protein kinase, functions as a regulator for the growth, proliferation, and metabolism of the cell. 
mTOR controls anabolic and catabolic processes in the cell by sensing the levels of nutrients and 
energy. Because the catalytic domain at the C-terminus of mTOR is similar to PI3K, mTOR 
belongs to the phosphatidylinositol (PI) 3-kinase (PI3K) related kinase (PIKK) family (Zhou, Luo, 
& Huang, 2010). mTOR has two different signaling protein complexes, mTORC1 and mTORC2, 
and each has different subunits, and both are inhibited by rapamycin. mTORC1 is composed of 
four proteins: the catalytic subunit, the regulatory associated protein of mTOR (Raptor), proline-
rich Akt substrate 40 kDa (PRAS40), and G-protein β-subunit-like protein (mLST8) (Figure 1-1). 
mTORC2 shares some similarities with mTORC1 in that both consist of the mTOR catalytic 
subunit and mLST8. However, mTORC2 has two different proteins that replace proteins in 
mTORC1. These proteins are the mammalian stress-activated protein kinase-interacting protein 1 
(mSin1), and the rapamycin-insensitive companion of mTOR (rictor). The major function of 
mTORC1 is to control the proliferation, survival and growth of the cell by activating its substrates 
S6K1 and 4E-BP1. However, mTORC2 serves as a regulator for the actin cytoskeleton and 
activator for Akt, which controls cell cycle, and growth (Zhou et al., 2010). 
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The specific role of each of the mTORC1 protein compartments is not fully determined yet 
(Laplante & Sabatini, 2009). Raptor, for example, is suggested to act as a regulator for mTORC1 
complex assembly (Hara et al., 2002). In addition, Raptor recruits protein substrates to mTOR 
through the interaction of Raptor with mTOR-signaling (TOS) motifs (Nojima et al., 2003). TOS 
motifs are short amino acid sequence motifs located on mTOR substrates (Fenton & Gout, 2011). 
mLST8 protein’s function is difficult to define. This is because the mTORC1 signaling was not 
disrupted by the elimination of mLST8 protein (Guertin et al., 2006). As mTORC1 activity 
decreases, PRAS40 becomes important. PRAS40 serves as a negative controller of mTORC1 
activity by binding to mTORC1 (Sancak et al., 2007; Wang, Harris, Roth & Lawrence, 2007). This 
binding prevents the interaction between mTORC1 and its substrates resulting in inhibition of 
mTORC1. When mTORC1 is activated, the association with PRAS40 is decreased through 
mTORC1 phosphorylating PRAS40 (Wang et al., 2007).  
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Figure 1- 1: The proposed mechanism for mTORC1 activation by amino acids. After amino acids 
are transported inside the cell, the mTOR1 is activated via the amino acid sensors (Kim, 2009). 
When mTORC1 is activated, it phosphorylates the downstream targets: the P70 ribosomal S6 
kinase 1 (S6K1), and the eukaryotic initiation factor 4E (eIF4E)- binding protein 1 (4E-BP1). 
When mTOR phosphorylates 4EBP1, it results in the release of eIF4E from 4EBP1. This allows 
eIF4E to bind to other translation factors. Thus, mTOR1 activation results in stimulating protein 
synthesis. Abbreviations: AA, amino acids, PRAS40, proline-rich Akt substrate 40 kDa, eEF2 
kinase, eukaryotic elongation factor2, Reheb, Ras-homolog enriched in brain, Raptor, regulatory 
associated protein of mTOR, PRAS40, proline-rich Akt substrate 40 kDa, mLST8, G-protein β-
subunit-like protein, eIF4E, eukaryotic translation initiation factor 4E. 
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1.2.2. Proposed Intracellular amino acids sensors for mTORC1 activation.  
        It is known that amino acids stimulate the mTORC1 pathway for protein synthesis. However, 
the exact mechanism of amino acid activation of mTORC1 is not fully understood due to the 
different amino acid structures and routes of metabolism (Kim, 2009). It was suggested that the 
cell is capable of sensing amino acids levels, which control protein synthesis and breakdown, via 
amino acids sensors. These sensors are either on the cell membrane, or within the cell (Kim, 2009). 
Three proteins have been proposed as amino acid sensors located inside the cell: hVps34, Rag 
GTPase, and MAP4K3. Each of these proteins plays a role in mTORC1 activation (Findlay, Yan, 
Procter, Mieulet & Lamb, 2007; Gulati et al., 2008; Sancak et al., 2008). The Vps34 protein, human 
vacuolar protein-sorting associated protein 34, belongs to class III PI3K and reacts with Vps15 
protein kinase to produce PtdIns (3) P (Gulati et al., 2008). Upon amino acids sensing, the activity 
of both Vps34 and PtdIns (3) P are elevated. In vitro, it has been reported that Vps34 is activated 
by amino acids through enhancing the Ca2+ influx (Gulati et al., 2008). In addition to Vps34, Rag 
protein was proposed to have a role in amino acids sensing. Rag activates mTOR1 through binding 
to Raptor which relocates mTORC1 to a region where the positive controller for mTOR activation, 
Rheb (Ras-homolog enriched in brain), is located in the intracellular region (Sancak et al., 2008). 
Another more recent study suggested that the Rag GTPase/ Ragulator complex is important for 
activating mTORC1 following translocation to the lysosomal membrane where mTOR1 interacts 
with the activator Reheb (Sancak et al., 2010). Furthermore, MAP4K3 protein, which is the 
mitogen-activated protein kinase, was suggested to have a role in amino acids signaling (Findlay 
et al., 2007). According to Findlay et al., 2007, it has been reported that amino acids acts as a 
regulator for MAP4K3 protein and the overexpression of MAP4K3 contributes towards enhancing 
the S6K phosphorylation which stimulates cell growth (Findlay et al., 2007).  
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 In conclusion, the mechanism of amino acids sensing and mTORC1 activation is not fully 
understood, and most of the experimental results are controversial (Findlay, et al., 2007; Kim, 
2009). 
 
1.2.3. Mechanism for mTORC1 activation by amino acids.  
       The initiation of the mTORC1 signaling pathway is stimulated via upstream signals such as 
nutrients (arginine and leucine), growth factors, oxygen and energy levels, and hormones (Laplante 
& Sabatini, 2009; Long, Lin, Ortiz-Vega, Yonezawa & Avruch, 2005). In the case of depletion of 
any of these factors, the mTORC1 signaling pathway is inhibited (Laplante & Sabatini, 2009). 
When mTORC1 is activated, it phosphorylates the downstream targets, P70 ribosomal S6 kinase 
1 (S6K1), and the eukaryotic initiation factor 4E (eIF4E)- binding protein 1 (4E-BP1) (Fingar, 
Salama, Tsou, Harlow & Blenis, 2002). Thus, mTORC1 activation results in stimulating protein 
synthesis (Bodine et al., 2001). Because of the TOS motif found in S6K1 N-terminal and 4EBP1 
C-terminal, mTORC1 is able to phosphorylate these substrates by associating Raptor with TOS 
motif (Schalm & Blenis, 2002). The activated S6K1 is responsible of stimulating the translation 
of mRNA (Ma, Yoon, Richardson, Jülich & Blenis, 2008). The un-phosphorylated 4EBP1 is 
considered a repressor for translation as it restrains the eukaryotic translation initiation factor 4E 
(eIF4E) from interacting with other factors that promote protein synthesis (Bodine et al., 2001; 
Gingras, Kennedy, O’Leary, Sonenberg & Hay, 1998). When mTOR phosphorylates 4EBP1, it 
results in the release of eIF4E from 4EBP1. This allows eIF4E to bind to other translation factors 
(Bodine et al., 2001). mTOR is not only responsible for stimulating ribosomal biogenesis, but also 
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stimulating elongation (Kim, 2009). This is achieved by inhibiting the function of the eukaryotic 
elongation factor2 (eEF2) kinase, which is the translation inactivating kinase, through the 
phosphorylation of eEF2 by S6K1 (Figure 1-1) (Redpath, Foulstone & Proud, 1996). 
 
1.2.4. Arginine and protein synthesis in neonates.  
       Yao et al. (2008) suggested that supplementing the diet with arginine increases piglet growth 
by activating the mTOR signaling pathway. They reported that arginine supplemented at 6% to a 
milk replacer diet enhanced the daily body weight gain and the skeletal muscle protein synthesis. 
The stimulation of skeletal protein synthesis was via the phosphorylation of mTOR and 4E-BP1 
which in turn increased the association of eIF4G with eIF4E to stimulate protein synthesis (Yao et 
al., 2008). Furthermore, arginine has been shown to stimulate protein synthesis in the neonatal 
small intestine. The effect of arginine on growth and protein synthesis was studied in vitro in 
neonatal porcine intestinal columnar epithelial cells (IPEC-J2). At physiological concentrations 
(0.1– 0.5 mmol/l), arginine increased the protein synthesis in cells via the stimulation of the mTOR 
pathway and the phosphorylation of downstream targets P70S6K and 4E-BP. Moreover, when 
IPEC-J2 cells were treated with rapamycin, protein synthesis was inhibited by 42%, suggesting 
that protein synthesis in the intestine was partially controlled by the mTOR pathway (Bauchart-
Thevret, Cui, Wu & Burrin, 2010). Another study evaluated the effect of arginine on intestinal 
protein synthesis in neonatal piglets with rotavirus enteritis. Arginine was supplied to a standard 
milk replacer diet at 0.4 g. k-1. d-1 with or without rapamycin and compared to controls. The 
intestinal protein synthesis was increased by 1.3 fold with arginine; also, arginine stimulated the 
activation of mTOR/p70S6k throughout the villus. However, the intestinal protein synthesis was 
inhibited when rapamycin was included, suggesting that arginine may be responsible for the 
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intestinal protein synthesis by activating p70S6k (Corl et al., 2008).  
 
In summary, arginine has a key role in stimulating protein synthesis via activating the mTOR 
pathway. As such, adequate arginine available to the intestinal enterocytes is of significant 
importance, particularly during intestinal injury in neonates. 
 
1.2.5. Rapamycin as inhibitor for protein synthesis.  
       Rapamycin is used as an anticancer agent, and is used to treat a number of different diseases 
such as coronary restenosis and rheumatoid arthritis (Laplante & Sabatini, 2009). The macrocyclic 
lactone rapamycin is derived from the bacterial species Streptomyces hygroscopicus which is 
found in soil. The first use of rapamycin was as an anti-fungal agent; however, recent studies 
suggest that rapamycin is also effective as an immunosuppressor (Zhou et al., 2010). Studies 
demonstrated that rapamycin forms a complex by binding to the intracellular receptor FKBP12. 
The formed complex then binds to the FKB12-rapamycin binding domain at the TOR proteins 
(Chen, Zheng, Brown & Schreiber, 1995; Choi, Chen, Schreiber & Clardy, 1996; Helliwell et al., 
1994; Kunz & Hall, 1993). Thus, the signaling of TOR protein is inhibited which in turn prevents 
the phosphorylation of the downstream substrates (Zhou et al., 2010). This inhibitory effect may 
be caused by disrupting the binding of raptor to mTORC1 which inhibits substrate binding (Oshiro 
et al., 2004) (Figure 1-1).  Thus, rapamycin is a useful tool to study factors which may alter the 
activity of the mTOR pathway, and influence the rate of protein synthesis in the small intestine. 
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1.3. Protein digestion and absorption. 
1.3.1. Protein digestion process.  
       Protein digestion is initiated in the stomach by the action of proteases. The predominant 
protease is pepsin, which is released from gastric cells in the form of a zymogen, pepsinogen, and 
is hydrolyzed to pepsin in the acidic gastric environment (Hinsberger & Sandhu, 2004; Kiela & 
Ghishan, 2016). Proteolytic activity produces a small amount of free amino acids, with the majority 
of the protein leaving the stomach and enters the duodenum as polypeptides (Hinsberger & 
Sandhu, 2004). The pancreas also contributes to protein digestion by secreting pancreatic enzymes 
in an inactive form. Pancreatic proteases are activated once they reach the duodenum by the brush 
border enzyme enteropeptidase. Furthermore, enteropeptidase activates trypsin, which in turn 
activates the other pancreatic proteases including elastase, chymotrypsin, and carboxypeptidases 
A and B. The main function of these enzymes is to hydrolyze the specific peptide bonds, resulting 
in free amino acids and oligopeptides with two to six amino acids residues. Mucosa-bound 
peptidases further hydrolyze the short peptides (Erickson & Kim, 1990). The end products of 
protein digestion are free amino acids, and oligopeptides (dipeptides, and tripeptides), which then 
are transported into the intestinal enterocyte by specific transporters on the brush border (Erickson 
& Kim, 1990; Hinsberger & Sandhu, 2004). 
 
1.3.2. Amino acids absorption at small intestine.  
       Nutrient absorption takes place over the length of the small intestine. However, the main 
location for peptide and free amino acids uptake occurs in the proximal jejunum (Bröer, 2008; 
Kiela & Ghishan, 2016). The uptake of amino acids by intestinal enterocytes requires transporting 
across the brush-border membrane by a passive or an active transporter (Kiela & Ghishan, 2016; 
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Stevens, Kaunitz & Wright, 1984). Amino acids may be utilized by the cell, or transported out of 
the cell through the basolateral membrane into the portal blood (Stevens et al., 1984). Once in the 
portal blood, amino acids may be picked up by the liver or distributed to peripheral tissues (Bröer, 
2008; Elwyn, Parikh & Shoemaker, 1968). 
 
1.3.3. Transporting free amino acids at brush border membrane.  
       The process of transporting amino acids in the brush border membrane is complex as it 
involves multiple transporters with different affinities to amino acids (Kiela & Ghishan, 2016). 
The brush border membrane has different amino acid transporter systems which include the neutral 
system (B0), the basic system (b0,+), the acidic system (X-AG), the iminoglycine system (IMINO), 
and the β-amino acid system (β) (Bröer, 2008). The neutral system (B0) is Na+ dependent, and is 
responsible for transporting neutral L-amino acids such as glycine, isoleucine, leucine, methionine, 
valine, phenylalanine, tryptophan and tyrosine (Bröer, 2008; Kiela & Ghishan, 2016; Sloan & 
Mager, 1999). The basic system (b0, +) is a Na+-independent transporter that carries neutral and 
cationic amino acids such as lysine, arginine, ornithine as well as cysteine. Additionally, the acidic 
system (X-AG) is a Na+-and H+-dependent carrier that transports anionic amino acids, especially 
aspartate and glutamate. Furthermore, the iminoglycine system (IMINO) is a Na+- and Cl-- 
dependent transporter and it is responsible for transporting imino acids including proline, 
hydroxyproline, and glycine. The β-amino acid system (β) is a Na+- and Cl-- dependent transporter 
that carries β-alanine and taurine (Bröer, 2008 ; Kiela & Ghishan, 2016).  
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1.3.3.1. rBAT/b0, + for transporting lysine, arginine, ornithine, and cysteine. 
 
       The main locations of the b0, +, and neutral and basic amino acid transporter (rBAT) proteins 
are the apical membrane of the epithelial cells of the small intestine and renal proximal tubules 
(Feliubadaló et al., 1999; Furriols et al., 1993; Pickel et al.1993; Mizoguchi et al., 2001). The b0, + 
transporter mediates the obligatory exchange of dibasic amino acids. This can be explained by the 
greater amino acid efflux binding affinity compared to the amino acid influx (Torras-Llort et al., 
2001). The association of b0, + with another amino acid transporter rBAT to form heterodimeric 
complex is necessary to fully activate b0, + for transporting cystine and dibasic amino acids 
(Sakamoto et al. 2009) (Figure 1-2). The heavy chain rBAT and light chain b0, + are connected by 
disulfide bonds (Chairoungdua et al., 1999). The heavy chain belongs to type II membrane protein, 
and it has one transmembrane domain and a large extracellular domain (Palacín & Kanai, 2004). 
The light chain such as b0, + AT, on the other hand, forms 12 putative transmembrane domains. 
The main function of the heavy chain is to facilitate the heterodimeric complexes targeting by the 
plasma membrane (Verrey et al., 2004). In contrast, the light chain forms the catalytic subunits, 
which function in substrate binding and transporting (Reig et al., 2002). Therefore, at the brush 
border of the small intestine, arginine and lysine are transported into the epithelial cells via 
rBAT/b0, + to be used by the cell or to cross the basolateral membrane for distribution by the portal 
vein. 
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Figure 1- 2: The association of b0, + with rBAT to form heterodimeric complex.  The heterodimeric 
complex is necessary to fully activate b0, + for transporting cystine and dibasic amino acids through 
an obligatory exchange system. Abbreviation: AA+, dibasic free amino acids, AA0, neutral free 
amino acids. 
 
1.4. Oligopeptides absorption at the small intestine. 
1.4.1. Oligopeptides transporting mechanisms.  
       The intestinal uptake of oligopeptides occurs through one of the three transport pathways 
which include the paracellular pathway, the cell penetration peptides pathway, and the PepT1 
mediated pathway (Gilbert, Wong & Webb, 2008). The paracellular pathway is defined as the 
movement of particles between cells, through the tight junctions (Gilbert et al., 2008). The cell 
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penetration peptides (CPPs) refer to the short sequences of peptide, whose function is to transport 
cargo in the form of peptides from the lumen to inside the cell (Gilbert et al., 2008; Munyendo, 
Lv, Benza-Ingoula, Baraza & Zhou, 2012). The paracellular pathway, and the cell penetration 
peptides pathway will not be discussed in this thesis.  
	  
1.4.2. PepT1- Mediated Pathway.   
        Peptide transporter 1 (PepT1) (SLC15A1) belongs to the proton-coupled oligopeptide 
transporter superfamily (Gilbert et al., 2008). PepT1 is located on the apical surface of intestinal 
epithelial cells (Saito & Inui, 1993).  It is responsible for transporting di- and tri-peptides into the 
cells (Freeman, Bentsen, Thwaites & Simmons, 1995). PepT1 is proton (H+) coupled transporter, 
and as such, the H+ gradient affects the activity of the transporter; an inward H+ gradient results in 
movment of oligopeptides. Moreover, PepT1 activation is influenced by the intracellular 
membrane potential. In other words, negative intracellular membrane potential activates PepT1, 
while a positive membrane potential deactivates it (Leibach & Ganapathy, 1996). When peptides 
along with H+ are transported into the enterocyte, the proton (H+) is pumped out of the cell through 
a Na+ /H+ exchanger. This Na+/H+ exchanger is also located on the intestinal brush border 
membrane, and it exchanges the intracellular H+ for extracellular Na+. Na+ inside the cell is 
transported across the basolateral membrane via Na+ /K+ ATPase pump. This assists in the 
exchange of three intracellular Na+ molecules for two extracellular K+, which in turn recovers the 
electrochemical gradient. When peptides are taken up by the intestinal cell, some are subjected to 
hydrolysis through intracellular peptidases to produce free amino acids.  Free amino acids are then 
transported through amino acid transporters on the basolateral membrane. Alternatively, peptides 
that are resistant to hydrolysis are also transported at the basolateral membrane, but via a “carrier-
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mediated mechanism” for peptide transport, that has not yet been clearly described (Gilbert et al., 
2008) (Figure 1-3). 
 
 
Figure 1- 3: PepT1- Mediated Pathway. PepT1 is proton (H+) coupled transporter, and it is 
responsible for transporting di- and tri-peptides into the cells. Abbreviation: AA, amino acid. 
 
1.4.2.1. PepT1 structure.  
       PepT1 is a 127 kDa protein that has histidyl groups as a catalytic domain (Daniel, 1996; 
Daniel, Spanier, Kottra, & Weitz, 2006; Fei et al., 1997). The histidyl catalytic domain is required 
for PepT1 activity in which the histidine side chain imidazole residue acts as a proton 
acceptor/donor (Leibach & Ganapathy, 1996). According to the hydropathy prediction, PepT1 has 
12 transmembrane domains including large extracellular hydrophilic loops within domains nine 
 18 
and ten (Daniel, 1996). In the luminal side, six putative N-glycosylation sites are located on the 
extracellular loop (N50, N406, N439, N510, N515, N532) (Stelzl, Baranov, Geillinger, Kottra & 
Daniel, 2016). In addition, the phosphorylation locations for protein kinase C (PKC) and A (PKA) 
are in the intracellular loop, in which phosphorylation of these promotes the highest rate of 
transport (Brandsch, Miyamoto, Ganapathy& Leibach, 1994; Van, Pan, Webb & Wong, 2005). 
Each terminus in PepT1 serves a significant function in substrate binding. One to six 
transmembrane domains form the N-terminus half which is involved in pH changes when substrate 
binds and peptide is transport through PepT1 (Terada, Saito, Sawada, Hashimoto & Inui, 2000). 
Furthermore, seven to nine transmembrane domains form the C-terminus and controls and set the 
substrate affinity (Fei et al., 1998). 
 
1.4.2.2. Transporter Affinity for Specific Peptides.  
       There are some features that are necessary for substrate binding to PepT1 (Brandsch, Knütter 
& Leibach, 2004). The charge on a peptide appears to affect its affinity for transport via PepT1.  
Neutral peptides have a higher affinity for PepT1 compared to positively or negatively charged 
peptides (Eddy, Wood, Miller, Wilson & Hidalgo, 1995). This was illustrated in Caco-2 cell 
monolayers in which the affinity for the cationic dipeptide lys-lys was lower than neutral 
dipeptides (Eddy et al., 1995). Furthermore, the intestinal PepT1 transporter is stereospecific, and 
it has much higher affinity for lys-lys dipeptides (or lys-lys-lys-tripeptides) than for peptides with 
D-amino acids (Brandsch et al., 2004). Lister, Sykes, Bailey, Boyd & Bronk, (1995) conducted an 
experiment using isolated rat jejunum perfused with dipeptides that were combinations of D- or 
L- alanine and/ or phenylalanine. They observed that dipeptides containing L-alanine at the N-
terminus position were transported efficiently even with D-phenylalanine in the C-terminus 
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position; however, if both amino acids were D-isomers, transport was negligible. This suggests 
that the chirality of amino acids is a contributing factor for PepT1 affinity, but transport of D-
amino acids appears possible as part of a peptide in the C-terminus position (Lister et al., 1995). 
Also, large hydrophobic amino acids at the N-terminus have high affinity for PepT1 (Vig et al., 
2006). For example, the binding affinity for Phe-Gly, Tyr-Gly, and Trp-Gly were higher compared 
to Gly-Gly. Similarly, when the C-terminal was a large hydrophobic amino acid, the dipeptide 
affinity for PepT1 was enhanced. For instance, enhancing Gly-X dipeptides affinity to PepT1 was 
linked to increasing the bulkiness and hydrophobicity on position 2. As a result, the affinities of 
Gly-Tyr and Gly-Phe were higher compared to Gly-Gly, Gly-Asp, and Gly-Glu (Vig et al., 2006). 
Aromatic amino acids, and proline on the C-terminus were also known to increase the binding 
affinity with PepT1 (Vig et al., 2006). 
 
1.4.2.3. PepT1 Distribution.  
       PepT1 distribution varies within the small intestine among species (Gilbert et al., 2008). 
PepT1 was found to be expressed throughout the length of the small intestine in mature dairy cows, 
sheep, pigs, and chickens (Chen, Wong, & Webb, 1999). In chickens, duodenum had the highest 
PepT1 expression, while in pigs, PepT1 was expressed in jejunum, and in ruminants, both jejunum 
and ileum expressed PepT1 (Chen et al., 1999). Such observations may be the result of high rates 
of protein digestion and absorption at these sites of the small intestine (Chen et al., 1999). In a 
human, PepT1 was found to be expressed along the length of digestive system with high expression 
in duodenum and jejunum (Terada et al., 2005). This is attributed to the fact that the majority of 
the digested protein in the intestinal lumen is in the form of oligopeptides (Terada et al., 2005). In 
addition, the cytoplasm of the mucosal cells is the major site where the cleavage of di/tripeptides 
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to free amino acids occurs (Kim, Birtwhistle & Kim, 1972; Terada et al., 2005). As a result, the 
high PepT1 expression in the upper small intestine illustrates the significance of peptide absorption 
from digested protein to sustain protein nutrition. (Terada et al., 2005).  In rabbit small intestine, 
the expression of PepT1 m-RNA was mostly located in duodenum and jejunum while ileum had 
the lowest expression. PepT1 expression is also found in the colon; however, it was very low 
compared to the small intestine (Freeman et al., 1995). In rats, the highest PepT1 expression was 
observed in four day old rats and declined by 28 days.  Furthermore, at four days of age, PepT1 
mRNA expression was 3.6 fold higher than in adult rats, which indicates the importance of peptide 
transportation during neonate life (Miyamoto et al., 1996). In young Yucatan piglets, PepT1 
expression and dipeptide uptake were reported during suckling age (1,2,3 weeks), and after 
weaning (6 weeks) (Nosworthy, Bertolo and Brunton, 2013). Piglets at suckling age showed the 
ability to transport dipeptide in both proximal and distal small intestines. Also, at suckling age, the 
colon expressed PepT1 mRNA. This adaptation is important since intestinal peptide absorption is 
crucial in the suckling period. Interestingly, post-weaning, the capacity for dipeptide uptake was 
high in the ileum relative to pre-weaned piglets. The change in the digestibility of the diet likely 
contributed to the expression of PepT1 in the ileum. Compared to sow milk, feeding a grain-based 
diet was much less digestible, so the lower gut was exposed to the protein hydrolysis products 
which may promote PepT1 expression (Nosworthy et al., 2013).  
 
1.4.2.4. Factors affecting PepT1 function and activity.  
       There are a variety of health or environmental factors that may affect PepT1 activity in the 
small intestinal epithelia such as diet, hormones, age, and malnutrition. Diet is one of the 
influencing factors that affects PepT1 expression in the small intestine. A high protein meal 
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produces large amounts of di- and tripeptides following digestion. The high concentration of 
luminal di- and tripeptides enhances the PepT1 gene expression, resulting in greater di- and 
tripeptides transportation into the epithelial cells (Adibi, 2003). An experiment was conducted by 
Erickson and his colleagues (1995) to compare PepT1 expression in rat intestines following low 
and high protein diets (Erickson, Gum, Lindstrom, McKean & Kim, 1995). They reported a 1.5- 2 
fold increase in PepT1 expression in the high protein diet group compared to the low protein group 
(Erickson et al., 1995). These results indicate that the high protein diet functioned as a substrate 
which induced PepT1 expression (Erickson et al., 1995). 
 
Hormones may also contribute to increasing peptide uptake by intestinal epithelial cells (IECs). In 
an in vitro study using Caco-2 cells, exposure to insulin triggered the uptake of glycyl-glutamine 
when insulin was provided at physiological concentrations. The authors suggested that the 
elevation of PepT1 population in the epithelial apical membrane was via the enhancement of the 
translocation of PepT1 from a preformed cytoplasmic pool (Thamotharan, Bawani, Zhou, & Adibi, 
1999 b). 
 
The nutritional status of the animal may alter the expression of PepT1 in the small intestine 
(Thamotharan, Bawani, Zhou & Adibi, 1999 a).  The effects of fasting on PepT1 expression was 
assessed in a study on rats. Rats were divided into two groups that were fed a standard diet or 
fasted for one day, and then brush-border membrane vesicles (BBMVs) were prepared from the 
harvested rat jejunum to measure glycyl-glutamine (Gly-Gln) absorption. Even though short term 
fasting (one day) resulted in a reduction in the mucosal cell mass, the uptake (Gly-Gln) was 
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enhanced by two fold.  Also, the PepT1 population and gene expression were three-fold higher in 
tissue from the fasted compared to the fed rats (Thamotharan et al., 1999 a).  
 
Total parenteral nutrition (TPN) has also been studied as a factor that affects the intestinal PepT1 
expression (Ihara, Tsujikawa, Fujiyama & Bamba, 2000). The effect of a TPN diet was examined 
by Ihara and his colleagues (2000) who fed Sprague-Dawley rats by TPN for 10 days. Results 
indicated that the TPN diet enhanced the PepT1 mRNA expression by 161% in jejunum, regardless 
of the intestinal atrophy that was caused by TPN feeding. They attributed the rise in PepT1 
expression in the intestine to the inadequate delivery of nutrition by this mode of feeding (Ihara et 
al., 2000). 
 
1.4.3. Nutritional significance of small chain amino acids absorption.  
       Compared to the free amino acids transporters, PepT1 is an effective method for transporting 
amino acids. The energy required for the transport of two or three amino acids into a cell is equal 
to that utilized for transporting a single amino acid. Moreover, the time required for transporting 
an equivalent amount of nitrogen as di- and tripeptides is less than that for the same composition 
of free amino acids, due to the rapid rate of absorption (Gilbert et al., 2008). A particular benefit 
of peptide transport is that patients with free amino acids transporter defects are capable of 
absorbing essential amino acids through PepT1 which avoids amino acids deficiencies (Adibi, 
1997). A common example is Hartnup disease, which is characterized by a disorder in the neutral 
amino acids transporter located in the small intestine and kidney. Patients with Hartnup disease 
are able to sustain a good nutritional state, despite the neutral amino acids transporter defect 
(Leonard et al., 1976).	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1.5. Role of PepT1 in trans-stimulation of b0, +antiporter. 
        
       Early evidence investigating amino acid and peptide transport suggested that the presence of 
peptides inhibited free amino acids uptake in the small intestinal cells (Fairclough et al., 1977). 
This was concluded based on a study that used a human intestinal perfusion model to measure free 
amino acids uptake by enterocytes when provided with high concentration of dipeptide. A thirty 
centimeter isolated segment of jejunum was perfused with either free amino acids mixture (24.9 
mmol/l) alone, or with high concentration of glycyl-glycine (100 mmol/l). During the perfusion 
process, samples from the perfused buffers were taken to measure amino acids and peptide 
concentrations. Researchers observed that free amino acids uptake was lower when provided with 
Gly-Gly compared to when provided alone. Although free amino acids and peptides were 
transported via different systems, Gly-Gly was able to inhibit the uptake of free amino acids 
(Fairclough et al., 1977). The inhibitory effect of the dipeptide Gly-Gly on free amino acids uptake 
was attributed to the free glycine that was released from Gly-Gly at the time of perfusion. When 
the researchers analyzed the luminally perfused buffers, they observed that Gly-Gly was partially 
hydrolyzed to free glycine which resulted in 18.6 mmol/l of free glycine and 60.7 mmol/l of the 
dipeptide Gly-Gly. They were unable to determine if the generated free glycine was from the 
actions of brush border or cytoplasmic peptidase. The concentration of free glycine from Gly-Gly 
was much higher than the concentration of free amino acids; therefore, the high free glycine 
concentration may have caused the inhibitory effect on free amino acids uptake (Fairclough et al., 
1977). However, recent studies have not supported this conclusion. A study by Wenzel, Meissner, 
Döring & Daniel, (2001) assessed the interaction between cationic amino acid transport and PepT1 
by using human intestinal Caco-2 cells. This group measured the uptake of the free L-arginine (10 
mmol/l) when incubated with specific dipeptides (10 mmol/l).  In these experimental conditions, 
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arginine absorption was not inhibited by dipeptides. Actually, the arginine uptake into cells was 
greater in the presence of dipeptides. They ascribed the findings to an interesting mechanism called 
trans-stimulation of the b0, +antiporter. The mechanism involves peptide transporter 1 (PepT1), 
which transports dipeptides into the enterocytes. Intracellularly, the dipeptide may be hydrolyzed 
to free amino acids, increasing the concentrations of free amino acid inside the cell. This, in turn, 
stimulates the b0, + antiporter, which initiates the exchange of the intracellular amino acid for 
luminal amino acid (Figure 1-2). The rate limiting step in trans-stimulation was the dipeptide 
hydrolysis inside the cell (Wenzel et al., 2001).  This was determined when cells were pre-
incubated with a hydrolysis resistant dipeptide, and the effect of trans-stimulation was inhibited, 
such that arginine uptake was not enhanced (Wenzel et al., 2001). Hence, PepT1 can provide 
greater amino acid absorption in two ways when compared to the other amino acids transporters. 
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Figure 1- 4: Trans-stimulation of b0, + antiporter. (1) Peptide transporter 1 (PepT1) facilitates the 
uptake of lys-lys into enterocytes. (2) Lys-lys may be hydrolyzed to free lysine, increasing its 
concentration inside the cell. (3) This in turn stimulates b0, + antiporter which initiates the exchange 
of the intracellular lysine for luminal arginine. 
 
Initially, PepT1 rapidly transports peptides that contain essential amino acids; as a result, it reduces 
competition among amino acids for a common transporter. Then, the intracellular hydrolysis of 
peptides increases the free amino acid concentration which initiates the trans-stimulation process, 
enabling greater free amino acid uptake (Wenzel et al., 2001). Another study also measured the 
permeability of gabapentin, which is an amino acid-like drug, using an in vivo intestinal perfusion 
model in rats. Nguyen and colleagues (2007) observed that the permeability of gabapentin was 
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enhanced when it was perfused with glycyl-glutamate (Gly-Glu) dipeptide. The authors suggested 
that when Gly-Glu is taken into the cell through PepT1, it may be hydrolyzed to glycine and 
glutamate. Glutamate may be converted into glutamine which may have been responsible for 
activating the trans-stimulation of b0, + antiporter. Thus, glutamine may be exchanged with luminal 
gabapentin (Nguyen, Smith & Fleisher, 2007). 
 
1.5.1. Trans-stimulation of b0, +antiporter in a neonatal model. 
       Most of the experiments that investigated the interaction between dipeptides and free amino 
acids were conducted in vitro (Wenzel et al., 2001). The trans-stimulation effect of the b0, + 
antiporter was also studied by our research group in vivo using a piglet model (Tennakoon, Bertolo 
& Brunton, 2011). That research assisted in understanding the interactions between dipeptides and 
free amino acids in a physiologically relevant model for human infants. By using an in situ gut 
loop perfusion model in Yucatan miniature piglets, L- arginine absorption was measured when 
perfused alone or with different concentrations of either lysyl-lysine, or lysyl-glycine (Tennakoon 
et al., 2011). Tennakoon et al. (2011) hypothesized that when arginine was perfused 
simultaneously with lysyl-lysine, arginine uptake by jejunal intestinal cells would be greater 
compared to when perfused alone or with free lysine. Results demonstrated that perfusing 10 
mmol/l arginine with 20 mmol/l lysyl-lysine resulted in 181% increase in arginine uptake by 
intestinal cells compared to when arginine was perfused alone. They attributed the increase in 
arginine uptake to the trans-stimulation of b0, +antiporter which facilitated the exchange of 
intracellular lysine for luminal arginine. However, compared to arginine alone, arginine uptake 
was not significantly improved (139%) when only 10 mmol/l lysyl-lysine was perfused with 10 
mmol/l arginine. They suggested that an important element for the trans-stimulation of b0, 
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+antiporter was the intracellular free amino acids concentration; 10 mmol/l lysyl-lysine may not 
have raised the intracellular free amino acids concentration above that threshold. Similarly, 50 
mmol/l lysyl-lysine did not result in the enhancement of arginine uptake (131%) by the intestinal 
cells. They observed that during the perfusion process, a significant amount of the lysyl-lysine 
underwent intraluminal hydrolysis producing high amounts of free lysine. Arginine and the high 
free lysine concentration are believed to have competed for the same transporter which could have 
resulted in undermining the enhancement of arginine uptake. The lysine concentration from lysyl-
lysine hydrolysis in the 10 mmol/l and 20 mmol/l lysyl-lysine conditions was low and likely not 
sufficient to compete with arginine (Tennakoon et al., 2011). Lysyl-glycine dipeptide was also 
used in the perfusion procedure to determine whether the cationic free amino acids concentrations 
had an effect on triggering the trans-stimulation of the antiporter b0, +. Enhanced arginine 
absorption was not observed when lysyl-glycine at different concentrations was perfused with 
arginine. The glycine concentration in mucosal tissue did not increase in parallel with the perfused 
lysyl-glycine concentration. This result may be attributed to the hydrolysis resistant lysyl-glycine 
dipeptide which effectively would lower the intracellular free lysine concentration and prevent the 
trans-stimulation of antiporter b0, (Tennakoon et al., 2011). 
 
To investigate the effects of both the intracellular hydrolysis of transported dipeptide and the 
intracellular concentration of free amino acid, the gut was perfused with 10 µmol/l amastatin which 
is an aminopeptidase inhibitor. Under the same experimental conditions but with the inhibitor, the 
enhanced uptake of arginine with 20 mmol/l lysyl-lysine did not occur. The inhibition of the 
enhanced arginine uptake with the peptidase inhibitor supports the role of dipeptides in inducing 
trans-stimulation of the antiporter b0, + (Tennakoon et al., 2011). 
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In summary, simultaneous delivery of 10 mmol/l arginine with 20 mmol/l lysyl-lysine resulted in 
enhanced arginine uptake by the intestinal cells via the trans-stimulation of antiporter b0, +. 
Delivering dietary amino acids as a combination of peptides and free amino acids may be 
beneficial for neonates to facilitate greater uptake by the intestinal mucosa, particularly for 
important amino acids such as arginine. 
 
1.6. Arginine and lysine antagonism. 
       Lysine and arginine antagonism may arise when lysine or arginine is provided in the diet in 
excess. Providing excess arginine or lysine may influence the metabolism of the other amino acid 
resulting in higher requirements (Ball, Urschel & Pencharz, 2007). Lysine is an essential amino 
acid, and in standard pig feeds, lysine is the first limiting amino acid due to the low concentration 
of lysine in cereal grain diets (Ball et al., 2007; Liao, Wang & Regmi, 2015). Lysine deficiency 
will negatively affect growth rate, and body weight (Chang & Wei, 2005). Lysine is involved in 
the synthesis of protein, peptides, non-peptide molecules, and carnitine (Liao et al., 2015; Wu, 
2013).  Also, lysine has a key role in regulating the metabolism of other amino acids (Shikata et 
al., 2007). Therefore, providing an ideal concentration of lysine is of particular importance in 
swine nutrition. 
 
Lysine-arginine antagonism has been reported for many different animals including rats, chicks, 
dogs, and guinea pigs (Austic & Scott, 1975; Baker, 1987; Czarnecki, Hirakawa & Baker, 1985; 
Ulman, Kari, Hevia & Visek, 1981). Lysine-arginine antagonism was attributed to the competition 
between lysine and arginine for uptake in the kidney and the intestine (Czarnecki et al., 1985). All 
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observations demonstrated that supplementing the diet with excess lysine caused lower growth 
rate which was reversed when arginine was supplemented (Czarnecki et al., 1985; Ulman et al., 
1981). Interestingly, lysine-arginine antagonism is controversial in young pigs. Supplementing 
excess arginine to pigs had adverse effects on lysine in term of decreased feed intake (Hagemeier, 
Libal & Wahlstrom, 1983).  Furthermore, supplementing a large amount of arginine to piglet diets 
had a negative effect on feed intake and weight gain. Moreover, adding lysine to the diet with 
excess arginine did not improve the negative effect of arginine (Southern & Baker, 1982). Baker 
(1987) also investigated the effect of supplementing lysine above the basal level on weight gain 
and feed efficiency. The basal diet was composed of 1.15% lysine and 0.53% arginine, which were 
within the range of requirement levels; lysine was added at 1.15%, 2.3% or 3.45% to the basal 
diet. Weight gain and feed intake were decreased in the basal diet supplemented with 2.3% and 
3.45%, while it was unaffected in the 1.15% diet when compared to the basal diet. However, the 
feed efficiency was similar among all groups supplemented with different lysine levels. Even 
though supplementing excess lysine resulted in an increase in plasma lysine concentration, it had 
no effect on plasma concentration of arginine, ornithine, and histidine. This indicates that lysine-
arginine imbalance is the main cause for growth depression, and it is not due to the lysine-arginine 
antagonism. Another study that was conducted by Tennakoon et al., (2011) examined the effect of 
perfusing 10 mmol/l arginine with 20 mmol/l free lysine in a gut loop model in piglets.  Arginine 
uptake was not impeded when compared to perfusing arginine alone, which suggests that lysine 
did not antagonize arginine.  Even when arginine was perfused with 50 mmol/l of lysyl-lysine 
which had undergone significant hydrolysis, it did not reduce arginine uptake compared to when 
arginine was perfused alone. Thus, no lysine-arginine antagonism was apparent (Tennakoon et al., 
2011). 
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While competition between lysine and arginine for uptake from the intestinal lumen may or may 
not be a problem for rapidly growing neonates, both are very important amino acids; a deficiency 
in either would interfere with optimal protein synthesis and growth.  In the preterm human infant, 
the risk of arginine deficiency is high, and can have potentially devastating consequences.  In the 
weaning piglet, the change from sow milk to solid feeding represents a period of intestinal injury, 
and growth faltering and diarrheal diseases are common at this time.  Providing arginine or lysine 
as free amino acids in the diet may be beneficial, but is expensive and providing one in excess may 
create negative effects on the metabolism of the other amino acids. To that end, providing lysine 
as a dipeptide may enhance arginine uptake while optimizing overall nitrogen retention.  A specific 
advantage of this combined approach in situations of intestinal injury in neonates, such as during 
infection or following IV feeding, may be enhanced uptake by the mucosa, leading to improved 
GI recovery and growth.   
 
1.7. The piglet as a research model. 
       Piglets are one of the best non-primate models to study neonatal nutrition (Puiman & Stoll, 
2008). Pigs and humans share similar anatomy of the gastrointestinal tract, with similar metabolic 
processes and proportionately similar nutrient requirements (Guilloteau, Zabielski, Hammon & 
Metges, 2010; Shulman, Henning & Nichols,1988). Also, the distribution and activities of 
intestinal enzymes in the neonatal piglet small intestine resembles those in human infants, all of 
which supports the use of the neonatal pig to study human intestinal development (Shulman et al., 
1988). With respect to nutrient uptake, pigs and human share many of the same intestinal 
transporters.  Specific to amino acid transport, Zhi et al. (2008) found that higher b0, + AT mRNA 
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expression occurred in the jejunum of piglets between 1 to 26 days of age, and it shared 88.9% 
amino acid homology with the human transporter (Zhi et al., 2008). Moreover, PepT1 expression 
was reported in piglets at suckling and after weaning throughout the small intestine (Nosworthy et 
al., 2013). Because neonatal piglets and human infants share the same amino acids transporters in 
the GIT, the piglet is a suitable model to study amino acid uptake in human infants.  
 
1.8. The in vivo intestinal perfusion model. 
       The gut loop model was developed to investigate the interaction between nutrients, 
transporters and gut functions. Adegoke, McBurney & Baracos, (1999) validated the gut loop 
model in a study that isolated multiple intestinal segments in six week old piglets. Intestinal 
segments were exposed to different nutrients via the lumen to study the effect on mucosal protein 
synthesis.  A study from our lab adapted the in situ gut loop model to measure PepT1 expression 
and the disappearance of the dipeptide glycyl-sarcosine from isolated small intestinal segments at 
suckling and post-weaned ages (Nosworthy et al., 2013). The gut loop model was also used to 
investigate the interaction between arginine and lysyl-lysine in the intestinal mucosal in miniature 
pigs (Tennakoon et al., 2011). The gut loop model involves isolating segments of small intestine 
by ligature, with inlet and outlet cannulas inserted for continuous perfusion of a nutrient solution; 
the blood supply remains intact (Tennakoon et al., 2011). The isolated loops in this model represent 
only a small portion of the animal’s total absorptive capacity; therefore, the perfused treatments 
should not have large systemic effects. The gut loop model permits the comparison of a number 
of varying treatments within the same animal, as multiple treatments are perfused concurrently. 
Therefore, a lower number of animals is required for each study, and each animal can serve as its 
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own control (Adegoke et al., 1999). In conclusion, the gut loop model has several advantages, and 
was validated as an appropriate model for the study of gut functions. 
 
	  1.9. Flooding dose to measure the rate of protein synthesis. 
       The flooding dose technique has been widely used to measure protein synthesis. The name 
“flooding dose” was devised because the method involves a “rapid injection of a large dose of 
tracee amino acid along with tracer amino acid” (El-Khoury, 1999). The large dose of amino acid 
results in flooding the free amino acid pool which serves to decrease the disparity between the free 
amino acid specific radioactivity in the extracellular and intracellular pools, as well as the amino 
acid acylated tRNA (El-Khoury, 1999). In other words, the flooding dose will flood every potential 
precursor pool (Garlick, Mcnurlan & Preedy, 1980). The utilization of the flooding dose eliminates 
the need to estimate the tracer’s specific radioactivity in the aminoacyl tRNA which is the “true 
precursor pool for protein synthesis” (Schaefer & Scott, 1993). One advantage of the flooding dose 
is that the specific radioactivity of the precursor pool is assumed to remain stable during the period 
when labeled amino acid is being incorporated into protein. The flooding dose technique is 
considered suitable for measuring short-term protein synthesis in rapidly turning over tissues such 
as the intestine (El-Khoury, 1999). Several amino acids have been used as the tracer for the 
flooding dose procedure, including tyrosine, valine, leucine, and phenylalanine (Schaefer & Scott, 
1993). Adegoke et al. (1999) successfully used a flooding dose of L-[2,6-3H] phenylalanine in a 
gut loop model to investigate the effect of nutrients on mucosal protein synthesis in six week old 
piglets. Luminal delivery of 3H-phenylalanine as the flooding dose tracer was also used in piglets 
to measure mucin and protein synthesis in the intestine (Nichols & Bertolo, 2008). Phenylalanine 
has been validated for use as the flooding dose tracer because changes in phenylalanine 
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concentration in the plasma will not affect the protein synthesis rate during the incorporation time 
(El-Khoury, 1999). Indeed, the flooding dose is a reliable technique to measure the rate of protein 
synthesis, especially in rapidly turning over tissues. 
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Chapter 2: Rationale, objective and hypothesis. 
 
2.1. Rationale.  
              Arginine and lysine are nutritionally important amino acids in neonates. Arginine serves 
as a precursor for important metabolites such as nitric oxide (NO), polyamines, and creatine (Wu 
& Morris, 1998; Wyss & Kaddurah-Daouk, 2000) and is conditionally essential in neonates 
(Brunton et al., 1999).  Furthermore, arginine has a role in activating the mTOR signaling pathway 
which contributes towards promoting neonatal growth (Yao et al., 2008). Lysine is an essential 
amino acid, and it is the first limiting amino acid due to the low concentration of lysine in cereal 
grain diet (Ball et al., 2007). Providing arginine or lysine as free amino acids in the diet may be 
beneficial, but providing one in excess may negatively influence the metabolism of the other amino 
acids. It would be advantageous to supplement amino acids in the form of dipeptides due to the 
low required energy and rapid absorption through PepT1 (Gilbert et al., 2008). We speculate that 
supplementing the diet with amino acids as peptides improves the absorption and the utilization of 
amino acids by the small intestine which assists piglets in growth during stressful events. 
Previously, we demonstrated in neonatal gut loops that simultaneous delivery of arginine with 
lysyl-lysine resulted in enhanced arginine uptake compared to the control condition (Tennakoon 
et al., 2011). Based on the results obtained in the previous study, the current study will determine 
if there are functional benefits to the greater arginine uptake by the small intestine, specifically as 
greater protein synthesis. 
 
2.2. Objectives and hypothesis. 
       The objectives of this research were: 
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1) to confirm that lysyl-lysine (lys-lys) enhances arginine absorption 
2) to determine whether enhanced arginine availability within the intestinal enterocytes leads 
to functional benefits, as demonstrated by the rate of mucosal protein synthesis 
3) to determine if greater mucosal protein synthesis in response to arginine uptake is mediated 
through the mTOR pathway. 
Hypothesis: 
The presence of the lysyl-lysine with L-arginine in the small intestinal lumen will lead to the 
functional advantage of greater mucosal protein synthesis via activation of mTOR, which is likely 
mediated through enhanced arginine absorption. 
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Chapter 3: Materials and Methods 
 
3.1. In vivo intestinal perfusion studies.  
 
3.1.1. Surgical preparation for the perfusion studies. 
       An in situ intestinal perfusion experiment was performed on sow-fed Yucatan miniature 
piglets between the ages of 16 and 21 days old (n = 12) which were obtained from Animal Care 
Services at Memorial University of Newfoundland (St. John’s, Canada). All procedures were 
approved by the Institutional Animal Care Committee (Memorial University of Newfoundland) 
and were in accordance with the guidelines of the Canadian Council on Animal Care. The 
experimental procedures were started immediately after the piglets were delivered to the animal 
facility.  This was done to prevent a fasting effect which might alter the function or expression of 
PepT1.  
Piglets (n=6) were pre-anaesthetized with an intramuscular (IM) injection of ketamine 
hydrochloride (20 mg/kg; Bimeda Canada, Cambridge, ON, Canada) and acepromazine (0.5 
mg/kg; Vetoquinol, Quebec, Canada). In order to reduce the airway secretions, an IM injection of 
atropine sulfate (0.05 mg/kg; Rafter Dex Canada, Calgary, AB) was also given to the animals. 
Finally, an IM injection of buprenorphine hydrochloride (0.03 mg/kg; Temgesic, Reckitt 
Benckiser Healthcare, UK) was administered as an analgesic before starting the experimental 
procedure.  Subsequently, an endotracheal tube was inserted into the trachea to maintain the 
airway. General anaesthesia was employed throughout the experiment using 0.8-1.5 % isoflurane 
(Abbott Laboratories Inc., Canada) delivered by a flow for oxygen at rate of 1.5 l/min. To ensure 
that we  maintain the piglets’ body temperature at 37 °C, the rectal temperature was measured 
every 15 minutes, and heat was delivered via a heating pad placed under the piglet. Similarly, heart 
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rate and the blood oxygen saturation were monitored during the experimental procedure. To 
prevent dehydration during surgery, a catheter was inserted in the jugular vein which allowed for 
0.9% saline administration at a rate of 13.5 ml/kg/h for the entire time of the surgery. When the 
piglet was anaesthetized and stable, the small intestine was exposed by laparotomy, and the 
ligament of Treitz was identified, which is considered to be the distal end of duodenum. The small 
intestine was measured longitudinally starting at the ligament of Treitz.  The first loop segment 
was initiated at 15 cm distal to the ligament, and measured 10 cm in length. The segment had inlet 
and outlet cannulas inserted at both ends (ID,1/16 in.; OD 1/8 in., Watson Marlow, Cornwall, UK), 
and the cannulas were secured by silk ligatures tied around the entire small intestine and cannula, 
which interrupted the continuity of the gut and prevented chyme from entering the isolated 
segment. Subsequently, five more segments of the proximal small intestine were similarly isolated 
with 50 cm between each segment, for a total of six loops per piglet. The mesenteric blood supply 
remained intact. The loops were flushed with warmed phosphate buffered saline (PBS) buffer 
(described below) to remove residual digesta. Once all of the loops were in place, the intestines 
were covered with gauze soaked in warm saline and plastic wrap to prevent insensible water losses.  
 
3.1.2. Perfusion study procedure. 
          The recirculating intestinal perfusion model was facilitated by a multi-channel peristaltic 
pump (Watson Marlow, Cornwall, UK) that was capable of pumping six different buffers 
simultaneously. The treatment buffers were kept warm during the perfusion procedure by a water 
bath set at 37 °C.  Each bottle containing the six treatment buffers had an inlet cannula that moved 
fluid from the bottle to the intestinal segment, and an outlet cannula returned buffer from the 
intestinal segment back into the bottle. Segments were perfused with one of the treatments buffers 
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(described below Table 3-1.) at rate of 1 ml/min for 120 minutes. For the first piglet in the 
experiment, the treatment buffers were randomly assigned to each loop; in subsequent 
experiments, the distribution of the treatment buffers was assigned to ensure an equal distribution 
of treatments by loop placement, to avoid the effect of location. During the experimental 
procedure, the treatment buffers were sampled before initiating the perfusion, and then every 15 
minutes during perfusion study. The perfusion study continued for 120 minutes.  At the end of the 
perfusion period, the 10 cm intestinal segments were excised by cautery and flushed with cold 
saline. The intestinal segments were placed on a glass plate on ice, cut lengthwise, and the mucosa 
was acquired by scraping the segments with a glass microscope slide. The weight of mucosa 
samples was measured and samples were frozen in liquid nitrogen, and stored at -80 °C for further 
analyses. 
 
3.1.3. Perfused treatments. 
       The treatments for each loop were prepared in PBS buffer (NaCl 144.6 mmol/l, Na2HPO4 15.9 
mmol/l, NaH2PO4 1.2 mmol/l, PH 7.4) (Sigma-Aldrich Canada Ltd, Oakville, ON).   Segments 
were perfused with one of the three treatment buffers: 10 mmol/l L-arginine (Ajinomoto North 
America, Inc, Raleigh, NC), 10 mmol/l arginine + 20 mmol/l lysyl-lysine (Bachem Americas, 
Torrance, CA), or 10 mmol/l arginine + 40 mmol/l L-lysine (Ajinomoto North America, Inc, 
Raleigh, NC) (Table 3-1). Segments perfused with 10 mmol/l arginine alone were considered the 
control condition. Each of the treatments were repeated in two loops within one pig.  In one of the 
two replicates, 3H-arginine (60 µCi [2.22 MBq] per 60 ml) was included to measure arginine 
disappearance. The second replicate was used to measure mucosal protein synthesis. To facilitate 
this measurement, the buffers were perfused without radioactive amino acid for the first 90 
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minutes.  Subsequently, the perfusion was stopped at 90 minutes and the buffers were replaced 
with treatments containing the same amino acids plus 3H-phenylalanine (60 µCi [2.22 MBq] per 
60 ml) (Moravek Biochemicals, CA, USA) and 2 mmol/l L-phenylalanine (Ajinomoto North 
America, Inc, Raleigh, NC). The labeling period with phenylalanine-containing buffers continued 
for 30 minutes.  
 
Six additional piglets underwent the identical protocol as described above; however, after piglets 
were anaesthetized, 0.75 mg/kg rapamycin (LC Laboratories, MA, USA) was delivered 
intravenously (IV) one hour prior to the intestinal perfusion study.  The 0.75 mg/kg rapamycin 
was dissolved in 5% dimethyl sulfoxide (DMSO) (Sigma-Aldrich Canada Ltd, Oakville, ON) and 
saline for IV delivery (Kimball et al., 2000). 
 
 
 Table 3- 1: Amino acid composition of the treatment buffers. 
 
*Perfused during the last 30 minutes with the same amino acids treatments. 
 
 
 
 
 
 
Amino Acids Treatment 
1 
Treatment 
2 
Treatment 
3 
Treatment 
4 
Treatment 
5 
Treatment 
6 
Arginine 10 mmol/l 10 mmol/l 10 mmol/l 10 mmol/l 10 mmol/l 10 mmol/l 
Lysyl-lysine  20 mmol/l   20 mmol/l  
Lysine   40 mmol/l   40 mmol/l 
Phenylalanine    2 mmol/l* 2 mmol/l* 2 mmol/l* 
3H-Arginine 1 µCi/l 1 µCi/l 1 µCi/l    
3H-Phenylalanine    1 µCi/l* 1 µCi/l* 1 µCi/l* 
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3.2. Analyses. 
 
3.2.1. 3H-arginine disappearance from luminal perfusates. 
       The 3H-arginine disappearance from luminal perfusate samples was measured by liquid 
scintillation counting to provide an estimate of 3H-arginine absorption by the intestinal cells. 100 
µl of perfusate sampled from the buffers at each time point was mixed with 5 ml ScintiVerse 
(Fisher Scientific, ON, Canada). The samples were then kept in the dark overnight. The following 
day, the disintegrations per minute (DPM) were measured for 10 minutes using a TriCarb 2810 
TR liquid scintillation counter (Perkin Elmer Life and Analytical Sciences, Downers Grove, IL). 
Finally, the arginine disappearance from perfusate samples was determined from the following 
formula: 
 
 
     Arginine disappearance = 	  "#$%&'	  "#$%()&*+,-./.  
  
          n0 = 
010%023	  24501016	  781761%42%081010%023	  983:;6  
 
Where: 
 
DPMt0 is the DPM in luminal perfusate sample prior to the perfusion procedure. 
 
DPMt120 is DPM in luminal sample at the end of the perfusion procedure. 
  
n0 is the arginine concentration in luminal perfusate samples prior to perfusion 
 
3.2.2. Amino acids concentrations in perfused buffers. 
       Perfusate samples were analyzed using the high performance liquid chromatography (HPLC) 
(Waters Inc., Mississauga, ON) to measure amino acids concentrations. The perfusate samples 
were diluted to 1:10 in order to bring the sample concentrations within the loading capacity of 
HPLC column. Then, 100 µl of the diluted samples were mixed with 20 µl of 2.5 mmol/l norleucine 
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internal standard (Sigma-Aldrich Canada Ltd, Oakville, ON). To allow any protein in the perfusate 
samples to precipitate, the perfusate samples were mixed with 1 ml of 0.5% trifluoroacetic acid 
(TFA) (Sigma-Aldrich Canada Ltd, Oakville, ON) in methanol (MeOH) (Fisher Scientific, 
Whitby, ON). Then the samples were centrifuged at speed of 4200 X g for 3 minutes at 4 °C 
(Eppendorf, NY, USA) in order to isolate the supernatant. The supernatant was poured into another 
labeled tube, and was frozen in liquid nitrogen and then vacuum dried (Thermo Fisher Scientific, 
MA, USA) overnight. The following day, 50 µl of fresh 20% triethylamine (TEA) (Sigma-Aldrich 
Canada Ltd, Oakville, ON), 20% methanol (MeOH) (Fisher Scientific, Whitby, ON), and 60% 
HPLC water was added to each sample. Then the samples were frozen with liquid nitrogen, and 
vacuum dried for one hour. After drying the samples, 20 µl of a derivatizing solution was added, 
that contained 10% water, 10% TEA, 70% MeOH, 10% phenylisothiocyanate (PITC) (Thermo 
Scientific, USA) and the samples were left for 35 minutes at room temperature to facilitate the 
labelling process. This resulted in PITC binding to the primary amine group of the free amino acids 
which produces phenylthiocarbamyl amino acids. After 35 minutes, the reaction was stopped by 
freezing the samples in liquid nitrogen and then the samples were vacuum dried overnight. On the 
following day, the samples were re-suspended in 200 µl of sample diluent containing 5 mmol/l 
Na2HPO4 (Sigma-Aldrich Canada Ltd, Oakville, ON), and 10% acetonitrile (Fisher Scientific, 
Whitby, ON) at pH 7.4. The samples were centrifuged at 3000 X g for 5 minutes at 4 °C. The 
resulting supernatant was transferred to 0.5 ml Eppendorf tube, and was centrifuged again at 3000 
X g for 5 minutes. After centrifuging for the second time, the supernatant was pipetted into 
Eppendorf which was placed into an HPLC vial.  
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Perfusate samples were analyzed by using the Pico-Tag method with HPLC. 100 µl of the 
derivatized sample was injected onto a reverse phase C18 column (Water, Mississauga, Ontario, 
Canada). The temperature of the column was maintained at 46 °C to optimize amino acids 
separation. UV detector was set at a wavelength of 254 nm to detect the phenylthiocarbamyl (PTC) 
derivatives. The running time of samples was 112 minutes since amino acids of interest such as 
lysine and lysyl-lysine have high retention times. The flow rate was 1 ml/min, and the buffer flow 
gradient protocol for lysyl-lysine separation is listed in table 3-2. Buffers A and B were prepared 
according to table 3-3, and 3-4. The eluent associated with arginine peak was fraction-collected in 
3 minute time windows by using Water Fraction Collector II (Water, Mississauga, ON). The 3 ml 
fractions were mixed with 5 ml ScintiVerse (Fisher Scientific, ON, Canada), and the 
disintegrations per minute (DPM) were measured for 10 minutes using a TriCarb 2810 TR liquid 
scintillation counter (Perkin Elmer Life and Analytical Sciences, Downers Grove, IL) to measure 
the radioactivity associated with amino acid. By using Empower 3 Software (Water, Mississauga, 
ON), the amino acids peaks were integrated. The amino acid concentrations were determined by 
comparing the area of amino acid to the area of the internal standard, norleucine.   
 
3.2.3. Tissue free amino acids concentrations in intestinal mucosa. 
       Amino acid concentrations in the mucosal tissue precursor pool were determined by HPLC. 
0.25 g of mucosa samples were homogenized with 1 ml of 2% perchloric acid. The samples were 
then centrifuged at 3000 X g for 15 minutes at 4 °C. The resulting supernatant was transferred to 
labeled scintillation vials. The homogenizing and centrifuging steps were repeated three times, and 
the final volume of supernatant was 3 ml. The resulting pellet was stored at -20 °C for subsequent 
analysis of protein-bound amino acid concentrations. For each supernatant, 25 µl norleucine 
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standard (25 mmol/l) was added, and the supernatant was vortexed. To neutralize the supernatant, 
1 ml was mixed with 125 µl of 2 mol/l K2CO3. Then it was centrifuged at 3000 X g for 3 minutes, 
and the resultant supernatant was then frozen in liquid nitrogen and freeze dried overnight. The 
following day, samples were derivatized and analyzed with HPLC analysis by following the same 
steps described in the previous section 3.2.2.  
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Table 3- 2:  Buffer flow gradient protocol for lysyl-lysine separation. 
 
 
 
 
 
 
 
 
Time (min) Flow (ml/min) %A %B Curve 
0.01 1.0 100.0 0.0 6 
13.5 1.0 97.0 3.0 11 
24.0 1.0 96.0 4.0 8 
30.0 1.0 91.0 9.0 5 
50.0 1.0 66.0 34.0 6 
66.0 1.0 66.0 34.0 6 
92.0 1.0 0.0 100.0 6 
102.0 1.0 0.0 100.0 6 
102.5 1.0 100.0 0.0 6 
112.0 1.0 100.0 0.0 6 
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Table 3- 3: Composition of buffer A. 
*pH was adjusted to 6.55 
 
Table 3- 4: Composition of buffer B. 
 
 
 
 
 
 
 
 
Ingredients Quantity 
HPLC water 4.0 l 
Sodium acetate 38 g 
Acetonitrile 100 ml 
Ingredients Quantity 
HPLC water 1.6 l 
Methanol 600 ml 
Acetonitrile 1.8 l 
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3.2.4. Mucosal protein synthesis rate. 
       To determine the mucosal protein synthesis rate, mucosal free and protein-bound amino acids 
were quantified by HPLC. The method of analysis of the mucosal free amino acid concentrations 
was described in the previous section 3.2.3.  
 
 To the protein pellet that resulted from tissue free amino acids preparation, 100 µl norleucine (25 
mmol/l) was added. After that, 1 ml of 6 mol/l HCl was added, and the pellet was disrupted with 
a glass rod. Samples were then transferred to labeled Pyrex tubes with screw caps. The tube which 
contained the homogenized pellet was rinsed with another 1.5 ml of 6 mol/l HCl to ensure that the 
entire sample was completely removed, and added to the Pyrex tube. The protein pellet was 
hydrolyzed at 110 °C for 24 hours in a drying oven. After 24 hours, the tubes were removed from 
the drying oven and were transferred to the fume hood to cool overnight. Once cooled, the 
hydrolysates were transferred to pre-weighed Erlenmeyer flasks. The Pyrex tubes were rinsed 
twice with HPLC water, and the final volume was brought to 6.3 ml. Samples were filtered using 
a 0.45 µm syringe filter into labeled vials. 1 ml of the filtered sample was placed in the vacuum 
oven to dry overnight.  
 
For both mucosal free and protein-bound amino acid analyses, 100 µl of fresh 20:20:60 TEA: 
MeOH: water was added to each sample. Samples were then frozen in liquid nitrogen and freeze 
dried for one hour. Then to each sample, 50 µl of derivatizing solution (10% water, 10 % TEA, 
70% MeOH, 10% PITC) was added, and samples were frozen in liquid nitrogen and freeze dried 
overnight. Before samples were injected onto the HPLC, they were re-suspended in 300 µl sample 
diluent (described above).  
 47 
Amino acid concentrations in the samples were analyzed by the Pico-Tag method with HPLC. 
Derivatized sample was injected onto a reverse phase C 18 column (Water, Mississauga, Ontario, 
Canada), using the same method and buffers as described above but with a run time of 90 minutes 
(Table 3-5) The eluent associated with the phenylalanine peak was fraction-collected in a 3 minute 
time window (Water Fraction Collector II, Water, Mississauga, ON) and scintillation counted as 
described above to measure the radioactivity associated with phenylalanine. 
 
The fractional synthesis rates of protein in the mucosa samples were calculated as follows: 
         
                     Ks = (SRAbound /SRAfree) x (1440/time) x 100  
Where          SRA = "#$	  01	  <=61>32321016<=61>32321016	  781761%42%081	  01	  %0??:6 
Ks= Fractional rate of protein synthesis, %/d. 
SRA bound= Specific radioactivity of bound phenylalanine in tissue, DPM/µmol. 
SRA free= Specific radioactivity of phenylalanine in the precursor pool, DPM/µmol. 
Time= Incorporation time in minutes. 
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Table 3- 5: Buffer flow gradient protocol, 90 minutes. 
 
 
 
 
 
 
 
 
 
Time (min) Flow (ml/min) %A %B Curve 
0.01 1.0 100.0 0.0 6 
13.5 1.0 97.0 3.0 11 
24.0 1.0 94.0 6.0 8 
30.0 1.0 91.0 9.0 5 
50.0 1.0 66.0 34.0 6 
66.0 1.0 66.0 34.0 6 
66.5 1.0 0.0 100.0 6 
78.5 1.0 0.0 100.0 6 
79.0 1.0 100.0 0.0 6 
90.0 1.0 100.0 0.0 6 
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3.2.5.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting. 
       Western blotting was used to detect the presence of mTOR protein in mucosa samples. 
Western blotting consists of three steps: gel electrophoresis to facilitate protein separation by 
molecular weight, protein transfer to a membrane, and incubation with antibodies to detect the 
protein of interest (Mahmood & Yang, 2012). 
 
3.2.5.1. Proteins extraction. 
       The cytosolic proteins in mucosa samples were extracted by using the lysis and extraction 
buffer, radioimmunoprecipitation assay (RIPA++) buffer (Mahmood & Yang, 2012). RIPA++ was 
prepared by first diluting the RIPA stock solution 1:10 (Cells Signelling Technology, Danvers, 
USA). Then protease inhibitors, phosphatase inhibitor and antioxidant agents (Sigma-Aldrich, St. 
Louis, MO) were added to the RIPA solution to make the RIPA++ buffer (Table 3-6). To initiate 
the extraction process, 400 µl of RIPA++ was first added to 1.5 ml labeled Eppendorf tubes on ice. 
0.15 g of mucosa was added to each Eppendorf. After adding samples to the RIPA++ buffer, they 
were allowed to thaw on ice for at least 20 minutes. The samples were then vortexed and 
homogenized with a micropestle while on ice (Geneaid, New Taipei, Taiwan) and then placed on 
a shaker (Boekel Scientific, PA, USA) at 4 °C for 30 minutes. The samples were then centrifuged 
at 10000 X g for 10 minutes at 4°C. The resultant supernatant was transferred to another labeled 
Eppendorf, and the pellet was kept and stored at -20 °C. Before storing the samples, the protein 
concentrations were determined as described in the following section. 
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Table 3- 6:  Preparation of the lysis buffer RIPA++ 
 
 
 
 
 
 
 
 
 
 
 
Reagents Function  Prepared stock 
concentration 
Working dilution 
Sodium Orthovanadate Phosphatase inhibitor 200 mmol/l  
 
1/200  
 
Dithiothreitol (DTT) Antioxidant 1 mol/l 
 
1/1000 
 
Leupeptin Phosphatase inhibitor 10 µg/µl 
 
1/100  
 
Aprotinin Protease inhibitor Diluted to 1/100 
 
1/100 
 
Sodium fluoride (NaF) Phosphatase inhibitor 2.5 mol/l 
 
1/50  
 
Beta-Glycerophosphate Phosphatase inhibitor 1 mol/l 
 
1/50  
 
 Phenylmethane sulfonyl 
fluoride (PMSF) 
Protease inhibitor 
 
200 mmol/l  
 
1/200  
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3.2.5.2. Determining the mucosal protein concentrations. 
       A standard curve was constructed to determine the mucosal protein concentrations. The 
purpose of determining the mucosal protein concentrations was to ensure equal protein loading 
into the electrophoresis gel. To construct the standard curve, different concentrations of standards 
were prepared from a stock bovine serum albumin (BSA) protein standard (200 mg/ml) (Sigma-
Aldrich, St. Louis, MO). Standard concentrations that were prepared were 0, 0.5, 1, 2, 3, 4 and 5 
mg/ml.  The PierceTM bicinchoninic acid assay (BCA) protein assay kit was used (Thermo 
Scientific, Illinois, USA).  A working solution was made by mixing proprietary Reagent A with 
Reagent B from BCA protein assay kit in 50:1 dilution, and 200 µl was added to each well in the 
96 well microplate.  All samples were run in duplicate. To each well, 5 µl of each of the prepared 
standards was added and mixed with the pipette. Before adding the mucosa samples to the reagent 
in the wells, the samples were first diluted to 1:10. The plate was covered with parafilm and 
incubated for 30 minutes at 37 °C. After that, it was cooled to room temperature. The absorbances 
were read by spectrophotometry (BioTek, VT, USA). Absorbances from the standards were used 
to construct the standard curve, which was then used to calculate the protein concentration in each 
sample.  
 
3.2.5.3. Preparing SDS-PAGE gel and gel electrophoresis. 
       After determining mucosa sample protein concentrations, the gel electrophoresis technique 
was used to separate proteins by molecular weight. Two gel cassette sandwiches were assembled 
by combing a short plate with a spacer plate.  The gel cassette sandwiches were then inserted into 
the casting frame, and placed in the casting stand apparatus (Mini-protean 3, Bio-Rad Laboratories, 
CA, USA). 15 ml of the separating gel was prepared (Table 3-7), which was enough to make two 
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1 mm gels. The separating gel was pipetted in between the short plate and the spacer plate, and 1 
cm was left as a space on the top of the gel. Water was poured on the top of the separating gel 
space. Afterwards, the separating gel was allowed to polymerize for one hour. After the one hour, 
the water was removed by moving small piece of filter paper in the space above the separating gel. 
The stacking gel was then prepared (Table 3-8), and was pipetted on the top of the separating gel. 
The 15 well comb was placed on the stacking gel, and then it was left to polymerize for 10 minutes. 
The electrophoresis apparatus was assembled, and filled with 700 ml of the running buffer which 
was made of 25 mmol/l Tris base (Thermo Scientific, Illinois, USA), 190 mmol/l glycine 
(Ajinomoto North America, Inc, Raleigh, NC), and 3.5 mmol/l sodium dodecyl sulfate (Sigma-
Aldrich, St. Louis, MO). The protein amount that was loaded onto the gel was 60 µg. To ensure 
equal volume for all samples, the final volume of samples was adjusted by the addition of RIPA++, 
and the 5x gel loading buffer. The added amount of RIPA++, and the 5x gel loading buffer depended 
on the highest calculated value of protein concentration in the sample set in which it was used in 
the equation to determine the amount of both the RIPA++, and the 5x gel loading buffer. 
 
Before loading samples into the gel, they were heated on a temperature block (Lanline Instruments, 
USA) at 90 °C for 3 minutes to denature the proteins. Then the BLUelf prestained protein ladder 
(FraggaBio, ON, Canada), and mucosa protein samples were loaded into the gel using sample 
loading pipette tips. The protein ladder is used as a reference to assist in estimating the molecular 
weight of the protein of interest. After loading the samples, the power supply was connected, set 
to 200 V, and run for 35 minutes. When the running was completed, the two gel cassette 
sandwiches were removed from electrophoresis tank, and by using the gel wedge (Bio-Rad 
Laboratories, CA, USA), the gels were removed by separating the glass plates. Then the stacking 
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gel was eliminated by the gel wedge, and the separating gel was soaked for 15 minutes in a cold 
transfer buffer which was made of 25 mmol/l Tris base without methanol (Thermo Scientific, 
Illinois, USA) and 190 mmol/l glycine (Ajinomoto North America, Inc, Raleigh, NC).  
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Table 3- 7: Preparation of the 10% separating gel  
 
      
  
 
 
 
 
 
Table 3- 8: Preparation of 6 ml of 3.5% stacking gel  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemical Quantity 
30 % Acrylamide 5 ml 
4X Resolving Gel Buffer pH 8.8 3.75 ml 
Deionized H2O 6.25 ml 
Tetramethylethylenediamine (TEMED) 
 
12 µl 
10 % Ammonium persulfate (APS)   110 µl 
Chemical Quantity 
30 % Acrylamide 0.7 ml 
4X Stacking Gel Buffer pH 6.7 1.5 ml 
Deionized H2O 3.8 ml 
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3.2.5.4. Western blot. 
       Before assembling the transfer sandwiches, fiber pads/sponge, Whatman 3 mm papers (Bio-
Rad Laboratories, CA, USA), and 0.2 µm nitrocellulose membranes papers (Bio-Rad Laboratories, 
CA, USA) were soaked in a transfer buffer with methanol which was made with 25 mmol/l Tris 
base (Thermo scientific, Illinois, USA), 190 mmol/l glycine (Ajinomoto North America, Inc, 
Raleigh, NC), and 20% methanol (Fisher Scientific, ON, Canada). The transfer sandwiches were 
assembled in the following order: soaked fiber pad first, the Whatman 3 mm papers, then the gel, 
membrane, Whatman 3 mm papers, and finally the pad. A roller was used to roll over the transfer 
sandwiches in order to remove any air bubbles. The transfer sandwiches were placed in the tank 
with ice, and the tank was filled with the transfer buffer with methanol. The transfer process was 
one hour long, and took place at 4 °C at 100 volts, and 350 mV. The transfer step allows the 
transfer of proteins from the gel to the membranes.  
 
3.2.5.5. Incubation with antibodies. 
       After completing the transfer process, the membranes were blocked with 3% milk in Tris 
buffered saline 0.05% Tween-20 (TBST) which was made of 5 mol/l NaCl (AFC, QC , Canada), 
1 mol/l Tris HCl (Thermo Scientific, Illinois, USA) at pH 7.8, and 20 % Tween-20 (Fisher 
Scientific, ON, Canada), at 55 °C for one hour. The membranes were then washed with TBST two 
times for three minutes. Then, the protein ladder was used as a reference to predict the position of 
the proteins of interest, and based on that the membranes were cut. The membranes were incubated 
with two antibodies: P-mTOR (Ser2448) rabbit pAb (Cells Signalling Technology, Danvers, USA) 
at 1/1000 dilution in 5% OmniPur® BSA, Fraction V Heat Shock Isolation (Millipore Ltd, ON, 
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Canada) in TBST, and actin rabbit (Sigma-Aldrich Canada Ltd, Oakville, ON) antibody at dilution 
1/7500 in 3% milk in TBST. The membranes were incubated overnight in the shaker at 4 °C. The 
following day, the membranes were washed with TBST 5 times for 5 minutes each, and then 
incubated at room temperature for one hour with the anti rabbit antibody secondary antibody 
conjugated to Horseradish Peroxidase   (HRP)   (Santa Cruz Biotechnology, Inc., TX, USA) at 
dilution of 1/7500 in 3% milk in TBST at room temperature. After incubating with the secondary 
antibody, the membranes were washed with TBST 6 times for 5 minutes each time. During the 
incubation time, immobilon western chemiluminescent HRP substrate (ECL) (EMD Millipore, 
MA, USA) was prepared by adding HRP substrate peroxide solution with HRP substrate luminal 
reagent at dilution of 1:1, and was kept at room temperature to warm up. Before visualizing the 
protein bands, the membranes were placed in ECL for 5 minutes, and then dried with filter paper. 
The protein bands were visualized by ImageQuant LAS 4000 (GE Healthcare, QC, Canada). The 
membranes were then stripped with a stripping buffer for re-probing. The stripping process was 
conducted in a water bath at 55 °C for one hour. Then, the membranes were washed with TBS (5 
mol/l NaCl, 1 mol/l Tris HCl ) 7 times for 5 minutes, and blocked again with 3% milk in TBST at 
55 °C for one hour. The membranes were incubated overnight in the shaker at 4 °C with mTOR 
rabbit pAb (Cells Signalling Technology, Danvers, USA) at dilution 1/1500 in 5% BSA in TBST. 
The following day, the membranes were washed with TBST, and incubated with the secondary 
antibody, and visualized by ImageQuant LAS 4000. During visualization of the bands, the 
ImageQuant LAS 4000 software automatically corrected for the background. The visualized bands 
were quantified by using Image Studio Lite software. 
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3.3. Statistical analyses.	  
       Data were analyzed by repeated measures one-way ANOVA followed by Tukey’s multiple 
comparisons test using Graph Pad Prism 7 (GraphPad Software, Inc., CA, USA).   For comparison 
of the luminal 3H-arginine uptake in the control condition (loops perfused with arginine alone) 
with and without rapamycin, data were analyzed by two tailed unpaired t-test using Graph Pad 
Prism 7.  Similarly, differences in the mucosal protein synthesis rate, and the ratio of the 
phosphorylated/un-phosphorylated mTOR protein, among different treatments in both animal 
groups treated with and without rapamycin were analyzed by using two tailed unpaired t-test using 
Graph Pad Prism 7. A t-test was considered suitable for these rapamycin comparisons because we 
were interested in comparing only the same treatment between both animal groups: arginine vs. 
arginine + rapamycin, arginine + lysyl-lysine vs arginine +lysyl-lysine + rapamycin, and arginine 
+ free lysine vs arginine + free lysine + rapamycin. Also, the two-tailed unpaired t-test was used 
instead of two-way ANOVA because when all treatments are compared together in both animal 
groups, this resulted in a loss of statistical power, therefore, affecting the ability of the test to detect 
differences.  For all tests, the mean values were considered significantly at P-values less than 0.05 
(P <0.05). 
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Chapter 4: Results 
 
4.1. Luminal 3H-arginine disappearance. 
 
       Arginine uptake by the intestinal mucosa in the gut loop perfusion model was calculated from 
the disappearance of 3H-arginine.  Compared to the control condition (10 mmol/l arginine alone), 
arginine uptake was 78% higher when co-perfused with 20 mmol/l lysyl-lysine (Figure 4-1). 
However, there was no significant difference in arginine uptake between the control treatment and 
free lysine treatment, or between the lysyl-lysine and free lysine treatments (Figure 4-1).  
 
 
Figure 4- 1: Luminal arginine uptake. Data were expressed as the percentage of control, which 
was the arginine disappearance from the luminal buffer when perfused alone (Arg). Values are 
mean ± SD, n=6 per treatment.  Data were analyzed by repeated measures one-way ANOVA 
followed by Tukey’s multiple comparisons test, *P < 0.05. Abbreviations: Arg, Arginine, Lys-
lys, Lysyl-lysine, Lys, Lysine. 
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4.2. Effect of rapamycin on luminal 3H-arginine disappearance. 
       Arginine disappearance from the perfused buffer was also measured in the piglets pre-treated 
with IV rapamycin. In this experiment, co-perfusion of arginine with lysyl-lysine or free lysine 
resulted in significantly greater uptake of arginine compared to the control (P < 0.05) (Figure 4-
2).  
 
Figure 4- 2: Luminal arginine uptake following pre-treatment with rapamycin. Data were 
expressed as the percentage of control, which was the arginine disappearance from the luminal 
buffer when perfused alone (Arg). Values are mean ± SD, n=6 per treatments. Data were 
analyzed by repeated measures one-way ANOVA followed by Tukey’s multiple comparisons 
test, *P < 0.05. Abbreviations: Arg, Arginine, Lys-lys, Lysyl-lysine, Lys, Lysine, Rapa, 
Rapamycin. 
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4.3. Comparison between luminal 3H-arginine disappearance in loops perfused with 
arginine alone with and without rapamycin. 
       Arginine tracer disappearance in the control loop was compared in piglets treated and not 
treated with rapamycin, to determine whether rapamycin affects arginine uptake. Arginine 
disappearance was not significantly different between the two experimental conditions, suggesting 
that rapamycin does not influence arginine uptake into the mucosa (P > 0.05) (Figure 4-3).	  
	  
	  
	  
Figure 4- 3: Comparison of luminal 3H-arginine disappearance in loops perfused with 
arginine alone.  Arginine tracer content in the control condition buffers (100 µl) following the 
perfusion study in piglets treated with and without rapamycin (n=6 per group). Values are mean 
± SD and were analyzed by two tailed unpaired t-test, P > 0.05. Abbreviations: Arg, Arginine, 
Rapa, Rapamycin. 
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4.4. Amino acid concentrations in the perfusion buffers. 
       Perfusate samples collected at time 0, 15, 30, 60, and 120 minutes were analyzed to assess the 
changes in amino acids concentrations over time.  Because no differences in arginine 
disappearance was apparent in piglets treated with rapamycin, data from both sets of piglets were 
pooled for some outcomes. 
 
Arginine concentration in perfusion buffer decreased over time in all three treatments, and there 
was no significant difference between treatments (P > 0.05) (Figure 4-4). 
 
Lysyl-lysine was subjected to hydrolysis in intestinal loops that were perfused with the dipeptide. 
This was demonstrated by the increased concentrations of free lysine over time (P > 0.05) (Figure 
4-5). 
 
The lysine concentration did not decrease with time in buffers that contained arginine and free 
lysine at the initiation of the study (P > 0.05) (Figure 4-6). 
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Figure 4- 4:  Arginine concentration over time in perfused buffers containing differing 
forms and concentrations of lysine. Values are means + SD (n=12). Data were analyzed by 
repeated measures one-way ANOVA followed by Tukey’s multiple comparisons test (P > 0.05). 
Abbreviations: Arg, Arginine, Lys-lys, Lysyl-lysine, Lys, Lysine. 
 
Figure 4- 5: Lysine concentration over time from lysyl-lysine hydrolysis in perfused 
buffers. Values are means ± SD (n=12). Data were analyzed by repeated measures one-way 
ANOVA followed by Tukey’s multiple comparisons test (P > 0.05). 
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Figure 4- 6: Lysine concentration in perfused buffers. Values are means ± SD (n=12). Data 
were analyzed by repeated measures one-way ANOVA followed by Tukey’s multiple 
comparisons test (P > 0.05). 
4.5. Free amino acid concentrations in intestinal tissue. 
       Mucosa samples that were obtained at the end of perfusion study were used to determine the 
amino acid concentrations in that tissue. Segments that were perfused with 3H-arginine with either 
arginine, lysyl-lysine, or free lysine were used to measure free concentrations of tissue arginine, 
ornithine, citrulline, glutamate, glutamine, proline and lysine.  
 
Although we measured higher arginine disappearance in intestinal segments co-perfused with 
lysyl-lysine, the tissue arginine concentration was not different, nor were any of the amino acids 
that may be synthesized from arginine (Table 4-1). However, there was a significant difference (P 
< 0.05) in lysine concentration in mucosa samples from loops that were perfused with either lysyl-
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lysine or free lysine, compared to the control loop that was not exposed to a luminal source of 
lysine (Table 4-1). 
 
Table 4- 1: Tissue free arginine, ornithine, citrulline, proline, glutamate, glutamine and 
lysine concentrations in intestinal mucosa. 
 Values are mean ± SD (n=6). Data were analyzed by repeated measures one-way ANOVA followed by Tukey’s multiple comparisons test *p < 
0.05. 
 
 
Amino Acid 
 
Arginine (10 mmol/l) 
 
Arginine + lysyl-lysine  
(10 mmol/l+ 20 mmol/l) 
 
Arginine + Lysine 
(10 mmol/l+ 40 mmol/l) 
 
Arginine (µmol/g) 
 
0.985 ± 0.68 
 
1.129 ± 0.73 
 
1.122 ± 0.69 
 
Ornithine (µmol/g) 
 
0.092 ± 0.025 
 
0.085 ± 0.016 
 
0.125 ± 0.043 
 
Citrulline (µmol/g) 
 
0.685 ± 0.55 
 
0.662 ± 0.59 
 
0.823 ± 0.74 
 
Proline (µmol/g) 
 
0.503 ± 0.22 
 
0.476 ± 0.20 
 
0.571 ± 0.18 
 
Glutamate (µmol/g) 
 
0.986 ± 0.14 
 
0.986 ± 0.11 
 
1.061 ± 0.14 
 
Glutamine (µmol/g) 
 
0.177 ± 0.06 
 
0.220 ± 0.09 
 
0.283 ± 0.12 
 
Lysine (µmol/g) 
 
0.52± 0.11 
 
3.3±1.55* 
 
4.0±1.65* 
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4.6. Mucosal protein synthesis.  
       The rate of mucosal protein synthesis was measured in segments that were perfused with 3H-
phenylalanine in addition to arginine, lysyl-lysine, or free lysine. The lysyl-lysine treatment 
resulted in significantly higher mucosal protein synthesis compared to the control treatment of 
arginine alone (P < 0.05) (Figure 4-7). Interestingly, the rate of mucosal protein synthesis tended 
to be different between the dipeptide and free lysine treatments (P = 0.055) (Figure 4-7). 
However, there was no significant difference in protein synthesis between the control condition 
arginine alone and the free lysine condition (Figure 4-7).  
 
 
Figure 4- 7: Mucosal fractional protein synthesis rates. Values are mean ± SD, n=6 per 
treatment. Data were analyzed by repeated measures one-way ANOVA followed by Tukey’s 
multiple comparisons test, *P < 0.05. Abbreviations: Arg, Arginine, Lys-lys, Lysyl-lysine, Lys, 
Lysine. 
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4.7. Effect of rapamycin on mucosal protein synthesis. 
 
       The mucosal protein synthesis rate was also measured in the small intestine in piglets pre-
treated with IV rapamycin. Mucosal protein synthesis was lowered by more than 60% in all amino 
acid treatments when rapamycin was given prior to the perfusion study (Figure 4-8). 
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Figure 4- 8: Mucosal fractional protein synthesis rates with and without rapamycin pre-
treatment. Values are mean ± SD, n=6 per treatment. *P < 0.05 by two tailed unpaired t-test. 
Abbreviations: Arg, Arginine; Lys-lys, Lysyl-lysine; Lys, Lysine; Rapa, Rapamycin. 
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4.8. Effect of rapamycin on mTOR pathway activation in the small intestine. 
       Western blotting was used to determine mTOR protein activation in mucosa samples that were 
obtained at the end of the perfusion procedure from the intestinal segments perfused with 3H-
arginine (i.e. three segments per piglet). Before proceeding to western blot analysis, protein 
concentration in mucosa samples was measured to ensure equal protein loading onto the gel. There 
were no significant differences in mucosal protein concentration among the treatments (Figure 4-
9). 
 
After running the gel electrophoresis and incubating with the primary and secondary antibodies, 
protein bands were visualized (Figure 4-10). The three membranes (Figure 4-10) represent 
phosphorylated mTOR (A), total un-phosphorylated mTOR protein (B), and actin (C), which is 
used as internal control. These bands represent the three treatments with and without rapamycin.  
The phosphorylation of mTOR protein was inhibited in all treatments in the group injected with 
rapamycin (Figure 4-10).  
 
Rapamycin significantly inhibited the mTOR activation pathway in both 10 mmol/l arginine (A) 
and 10 mmol/l arginine with 40 mmol/l free lysine (C) (P < 0.05) treated loops (Figure 4-11), with 
a tendency for a lower ratio of the phosphorylated: nonphosphorylated mTOR in the rapamycin-
treated lysyl-lysine loop (B) (P = 0.09) (Figure 4-11). 
 
We expected that the intensity of mTOR band should be similar in both groups: with and without 
rapamycin. However, we observed low intensity band of mTOR in the rapamycin treated group 
when compared to non rapamycin treated group.  
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. 
 
 
 
 
Figure 4- 9: Mucosal protein concentration. Values are means + SD (n=12) and data were 
analyzed by repeated measures one-way ANOVA followed by Tukey’s multiple comparisons P 
> 0.05. Abbreviations: Arg, Arginine; Lys-lys, Lysyl-lysine; Lys, Lysine. 
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 (A)                                             with rapamycin               without rapamycin      KDa 
 
 
(B) 
 
(C) 
 
 
 
Figure 4- 10: Western blot membrane for (A) phosphorylated (B) nonphosphorylated mTOR 
protein (molecular weight is 289), and (C) actin protein (molecular weight is 42)  for samples 
treated with and without rapamycin among different treatments. The phosphorylation of 
mTOR protein was inhibited in all treatments in the group given IV rapamycin. Actin was used as 
the internal control. The antibodies detected more than one band because P-mTOR and mTOR 
were polyclonal antibodies. Bands were selected by comparing the molecular weight of the protein 
of interest to the KDa values in the BLUelf prestained protein ladder. 
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Figure 4- 11: The ratio of phosphorylated to nonphosphorylated mTOR with and without 
rapamycin. Values are mean ± SD, n=6 per treatment. *P < 0.05 by two tailed unpaired t-test. 
Abbreviations: Arg, Arginine; Lys-lys, Lysyl-lysine; Lys, Lysine; Rapa, Rapamycin. 
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Chapter 5: Discussion 
5.1. Luminal 3H-arginine uptake in intestinal loops perfused with lysyl-lysine. 
 
       We confirmed the findings by Tennakoon et al. (2013) that lysyl-lysine enhanced arginine 
absorption in the neonatal piglet’s small intestine. Our results indicate that the luminal 3H-arginine 
uptake in miniature piglets was significantly higher in intestinal loops perfused with 10 mmol/l 
arginine and 20 mmol/l lysyl-lysine (178%) compared to the control condition of arginine alone 
(Figure 4-1). The enhanced arginine uptake by the dipeptide, lysyl-lysine, may be explained by 
the trans-stimulation of the b0, + antiporter. PepT1 facilitates the uptake of lysyl-lysine into 
enterocytes. Lysyl-lysine can then be hydrolyzed by intracellular peptidases to free lysine, 
increasing its concentration inside the cell. This free lysine in turn may stimulate the b0, + antiporter 
which initiates the exchange of the intracellular lysine for luminal arginine, resulting in enhanced 
arginine uptake. Also, we observed the same results under different experimental conditions, when 
rapamycin was infused intravenously prior to the perfusion study.  Under those conditions, co-
perfusing 20 mmol/l lysyl-lysine with arginine again resulted in the highest arginine uptake (179%) 
compared to the control condition (Figure 4-2). The results from these two experiments were very 
similar to what was observed previously in a study that was done in our lab (Tennakoon et al., 
2011). When 20 mmol/l lysyl-lysine was co-perfused with 10 mmol/l arginine in an in situ gut 
loop model in miniature piglets, arginine absorption by intestinal cells was enhanced compared to 
the control condition (Tennakoon et al., 2011). In addition, a similar observation was reported in 
human intestinal Caco-2 cells (Wenzel et al., 2001). When Caco-2 cells were incubated with lysyl-
lysine (10 mmol/l) or free amino acids, the uptake of the free L-arginine was greater with the 
presence of dipeptides (Wenzel et al., 2001).  
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We also measured the mucosal tissue free amino acid concentrations in intestinal segments that 
were perfused with arginine with or without lysyl-lysine. We found that lysine concentration was 
almost six times higher in segments exposed to lysyl-lysine compared to the control condition with 
no lysine or dipeptide (Table 4-1). This finding supports the concept that high intracellular lysine 
generated from lysyl-lysine hydrolysis was a factor in initiating the trans-stimulation of b0, + 
antiporter. Similar results were reported in the study by Tennakoon et al. (2011). In that study, 
when arginine was perfused with different concentrations of lysyl-lysine (10 or 20 mmol/l), the 
lysine concentration in tissue was only significantly higher in the 20 mmol/l condition compared 
to the control condition. The authors suggested that the concentration of intracellular lysine was 
the main factor in initiating the trans-stimulation of b0, + antiporter. As a result, they only observed 
higher arginine uptake by mucosa cells in the 20 mmol/l lysyl-lysine condition, but not the 10 
mmol/l. They attributed the absence of enhanced arginine uptake with the 10 mmol/l lysyl-lysine 
to the possibility of the low lysine concentration which was unable to stimulate the trans-
stimulation of b0, + antiporter (Tennakoon et al., 2011). 
 
We also observed in the current study that free lysine increased in the buffer in the lysyl-lysine 
treatment. By the end of the perfusion process, lysine concentration in the buffer was ~7.5 ± 2.3 
mmol/l (initial concentration was ~ 0 mmol/l) . The free lysine may have come from the transport 
of intracellular lysine to the lumen by the b0, + antiporter to exchange for arginine. 
 
In conclusion, co-perfusing lysyl-lysine with arginine likely stimulates the trans-stimulation of b0, 
+ antiporter which results in greater arginine uptake by mucosal cells.  It would be interesting to 
determine if other dipeptide/free amino acid combinations also exhibit the same beneficial effect, 
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or if this arginine/lysyl-lysine relationship exists in other circumstances, such as during intestinal 
injury. 
 
5.2. Luminal 3H-arginine uptake in intestinal loops perfused with free lysine. 
       Lysine-arginine antagonism describes the competition between lysine and arginine for 
transport in the intestine (Czarnecki et al., 1985). Lysine-arginine antagonism has been 
documented in a number of different animals including rats, chicks, dogs, and guinea pigs (Austic 
& Scott, 1975; Baker, 1987; Czarnecki et al., 1985; Ulman et al., 1981).  However, in young pigs, 
lysine-arginine antagonism is controversial (Baker, 1987; Hagemeier et al., 1983). In this study, 
we did not observe lysine-arginine antagonism. Co-perfusing 10 mmol/l arginine with 40 mmol/l 
free lysine did not inhibit arginine uptake.  Indeed, arginine uptake when delivered with free lysine 
was almost 50% greater than the control condition (Figure 4-1), although not significantly 
different. In the second experiment when piglets were pretreated with rapamycin, the delivery of 
arginine with 40 mmol/l free lysine significantly enhanced arginine uptake compared to the control 
condition (Figure 4-2). There was less variability in the response to the free lysine in the rapamycin 
experiment, which likely facilitated the statistical difference.   
 
In the study by Tennakoon et al. (2011), they also did not observe lysine-arginine antagonism 
using the gut loop model and delivering 20 mmol/l free lysine with arginine (Tennakoon et al., 
2011).  Similar to our study, perfusing arginine with free lysine resulted in more arginine uptake 
(i.e. ~ 123-130% of the control condition), but in that study, it was not significantly different from 
the control condition (Tennakoon et al., 2011). The absence of lysine-arginine antagonism in the 
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situ model may be attributed to the activity of another transporter that is responsible for 
transporting cationic amino acids in intestinal piglets (Deves & Boyd, 1998). 
 
We also measured the concentration of free lysine in mucosal tissue, after the tissue was exposed 
to lysine during the perfusion study. Not surprisingly, the lysine concentration was significantly 
higher when 40 mmol/l of free lysine was co-perfused with arginine compared to the control 
condition (Table 4-1). Although there was a high lysine concentration in the mucosal tissue, we 
did not observe enhanced arginine uptake when compared to the control condition in the first 
experiment.  We anticipated that the presence of high lysine concentration in the buffer may 
compete with arginine for the same b0, + transporter for uptake, but this was not the case in all 
conditions. Indeed, we did not observe any effect of perfusing lysine with arginine, and lysine did 
not impair arginine uptake in miniature pig’s small intestine. 
 
5.3. Mucosal protein synthesis.  
       We hypothesized that the presence of the lysyl-lysine with arginine in the small intestinal 
lumen will lead to the functional advantage of greater mucosal protein synthesis, which is likely 
mediated through enhanced arginine absorption. We measured the rate of mucosal protein 
synthesis in samples that were acquired from intestinal segments which were perfused with 3H-
phenylalanine. The delivery of lysyl-lysine with arginine resulted in the highest rate of mucosal 
protein synthesis (47%/d) compared to the other two treatments (Figure 4-7). Although not 
statistically different, the arginine uptake with free lysine tended to be ~ 50% greater than the 
control; however, this did not translate into greater protein synthesis, which was similar between 
free lysine (16%/d) and the control condition (21%/d) (Figure 4-7). These rates of mucosal protein 
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synthesis tend to be lower than literature values for fed piglets (Bauchart-Thevret et al, 2010).  This 
was likely due to the model wherein only arginine and lysine were perfused through the gut rather 
than a balance of amino acids; this would limit protein synthesis.  The higher rate of protein 
synthesis with the lysyl-lysine may be due to greater arginine availability for incorporation into 
proteins, or greater activation of the mTOR pathway (Bauchart-Thevret et al., 2010); however, the 
differences in rate of protein synthesis are much larger than the differences measured in arginine 
uptake in the various experimental conditions.  An alternate explanation involves a direct effect of 
the lysyl-lysine dipeptide on mTOR activation.  A recent study measured the effects of lysyl-lysine 
in IPEC-J2 cells harvested from neonatal piglet jejunum.  Exposure to different concentrations of 
lysine and lysyl-lysine were used to measure mTOR activation (Yin et al., 2016). The authors 
reported that high lysine concentration (5 mmol/l) lowered the phosphorylation of mTOR, while 
exposure to high lysyl-lysine (5 mmol/l) enhanced mTOR activation (Yin et al., 2016).  The 
dipeptide lysyl-lysine may have a role in mTOR pathway activation and nutrient sensing, thus 
directly modifying protein synthesis in the small intestine (Yin et al., 2016).  
 
5.4. Mucosal protein synthesis with rapamycin. 
       One of the objectives of this study was to determine if the mucosal protein synthesis in 
response to arginine uptake was mediated through the mTOR pathway. The rate of mucosal protein 
synthesis was measured in neonatal piglets after they were pretreated with rapamycin inhibitor. As 
predicted, rapamycin significantly inhibited the mucosal protein equally amongst all treatments 
(Figure 4-8). A similar observation was reported in an in vitro study which used neonatal porcine 
intestinal epithelial cells (IPEC-J2) (Bauchart-Thevret et al., 2010). When the cells were exposed 
to varying arginine concentrations (0, 0.1, 0.5, 1.0 mmol/l), there was a stimulation of the mTOR 
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pathway, and the rate of protein synthesis increased by 76% compared to the control condition. 
However, the highest protein synthesis rate was at the physiological concentrations of arginine, 
0.1– 0.5 mmol/l. Moreover, when IPEC-J2 cells were treated with rapamycin at different 
concentrations (1-1000 nmol/l), protein synthesis was inhibited compared to the control condition. 
However, protein synthesis was significantly inhibited by 42% after treating the cells with 
rapamycin at concentrations of 1-10 nmol/l. These results suggest that protein synthesis in the 
intestine was partially controlled by the mTOR pathway (Bauchart-Thevret et al., 2010). 
 
In summary, we observed that the intestinal proteins synthesis was equally inhibited among all 
treatments after pre-treating piglets with IV rapamycin. Our results support previous findings that 
the protein synthesis in the small intestine mucosa is stimulated by arginine availability.  
 
5.5. mTOR pathway inhibition by rapamycin. 
       To further clarify the roles of arginine and mTOR in stimulating protein synthesis, western 
blotting was used to assess the activation status of mTOR pathway intermediates in the presence 
and absence of rapamycin. Rapamycin significantly inhibited the mTOR pathway activation in the 
arginine alone and arginine with free lysine conditions (Figure 4-11). For the arginine plus lysyl-
lysine condition, ratio of phosphorylated/nonphosphorylated mTOR was not significantly 
different, despite an 87% lower ratio with rapamycin (Figure 4-11).  
 
We expected that the intensity of mTOR band would be similar in both groups, with and without 
rapamycin. Because the intensity of the mTOR band was low in the rapamycin treated group when 
compared to the non-rapamycin group, we may have overestimated the ratio of p-mTOR/mTOR 
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in rapamycin treated group (Figure 4-10) (Figure 4-11). Despite this potential error, we still 
observed significant inhibition. One possible reason that may have contributed to the low intensity 
mTOR band was that rapamycin may have changed the antibody binding site on- mTOR.  
 
The decrease of the ratio of phosphorylated/nonphosphorylated mTOR follows the same pattern 
of the mucosal protein synthesis inhibition data. Rapamycin lowered the level of 
phosphorylated/nonphosphorylated mTOR by 80% or more when piglets were pre-treated with IV 
rapamycin. Similar results were reported in an in vitro experiment which demonstrated that 
arginine (0.5 mmol/l) activated mTOR signaling in neonatal porcine IEC (IPEC-J2) cells, and the 
addition of rapamycin (10 nmol/l) affected mTOR and its downstream target activation by 
decreasing the phosphorylation levels which also in turn decreased the mucosal protein synthesis 
(Bauchart-Thevret et al., 2010). Moreover, another study that was done in arginine-supplemented 
neonatal piglets with rotavirus enteritis demonstrated that rapamycin decreased the relative 
phosphorylation level of mTOR/p70S6k by 80% in the small intestine which was also reflected in 
the mucosal protein synthesis (Corl et al., 2008). 
 
We expected that mTOR activation would parallel the stimulation of mucosal protein synthesis.  
In other words, since the protein synthesis in the small intestine is mediated by the mTOR signaling 
pathway, the level of the activated mTOR should be mirrored by the level of protein synthesis 
stimulated in the small intestine. According to our protein synthesis data (in the absence of 
rapamycin), we assumed that we would find higher mTOR activation in loops perfused with 
arginine and lysyl-lysine compared to arginine alone or free lysine. However, results were 
unexpected, and what we observed was completely the opposite of the protein synthesis data. The 
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mTOR activation was higher with arginine alone and free lysine. As a result, the pattern of mTOR 
activation among different treatments without rapamycin (Figure 4-11) did not parallel the 
mucosal protein synthesis data (Figure 4-7). This may be because the relationship between protein 
synthesis and mTOR is not linear and that mTOR was already maximally activated. Another reason 
that may be that the amino acids that were readily available in the mucosa were not sufficient to 
support any greater protein synthesis, because we did not perfuse the full profile of amino acids 
through the loops. 
 
We also attempted to measure other proteins in the mTOR pathway which are the downstream 
targets P70S6K and 4E-BP1; however, we did not report the results. During western blot analysis, 
we encountered multiple methodological problems.  After incubating with the primary P70S6K 
and 4E-BP1 and secondary antibodies, we did not visualize any bands on the membrane; this may 
be because of a failure of antibody binding to the protein in the membrane. The reason for not 
visualizing any bands could be related to the sample concentrations or the antibody concentrations 
used. However, we tried multiple sample concentrations and antibody concentrations, and we still 
did not produce any bands.  Another reason could be the antibody itself, which is not specifically 
for porcine protein detection; as a result, it may not have bound to the protein on the membrane. It 
is important in the future to compare the the antigenic epitopes used for the generation of P70S6K 
and 4E-BP1 antibodies with the porcine sequences, to verify whether or not there is cross reactivity 
between antibodies and the porcine proteins. Eventually, attempts to quantify P70S6K and 4E-
BP1 were abandoned due to time and funding constraints.  
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In summary, piglets pre-treated with IV rapamycin demonstrated a decrease in the ratio of 
phosphorylated/nonphosphorylated mTOR protein among all treatments when compared to the 
non-rapamycin-treated group. The decrease in mucosal protein synthesis in the neonatal piglet 
small intestinal mucosa is likely due to the mTOR inhibition by rapamycin. Our results 
demonstrated that when more arginine substrate was available, protein synthesis was stimulated. 
Nevertheless, our results failed to demonstrate that arginine stimulates mTOR since we did not 
include zero or low arginine treatment.  
 
 
 
5.6. Limitations and modifications. 
 
       The gut loop model was used in piglets to measure intestinal amino acid uptake. The gut loop 
model is an excellent design to investigate multiple experimental conditions in one animal by 
having multiple intestinal segments perfused with different treatments simultaneously. The main 
purpose of this study was to define the amino acids interaction at the level of the mucosa in the 
small intestine which would ultimately assist in designing optimal diets to support piglet growth. 
Perfusing multiple treatments at the same time is also considered one of the limitations of the study 
design because it is difficult to determine how each treatment will contribute to overall piglet 
performance. In order to be able to interpret the effect of each treatment on growth, protein 
synthesis, and overall amino acids metabolism in tissues, it would be necessary to supply only one 
treatment to one animal. Moreover, by perfusing multiple treatments in the same animal, it is 
impossible to measure plasma amino acids profile. Measuring the plasma amino acids profile 
would assist in supporting the reported results, in terms of greater amino acids uptake by intestinal 
cells being reflected in the blood. Also, a single treatment would facilitate determining the form 
 81 
of amino acids that enters the circulation (dipeptide vs. free amino acid) after exiting the basolateral 
side of the intestinal cells. 
 
Finally, the perfused buffers were composed of only PBS and arginine, arginine and lysyl-lysine, 
or arginine and free lysine, which is likely not the ideal nutrient profile to support mucosal protein 
synthesis.  Interestingly, the highest rate of protein synthesis measured in this study (46%/d) was 
only marginally lower than that reported by Nichols et al. (~53%) in a perfusion study with 
neonatal piglets that included a balance of amino acids in the buffers (Nichols et al., 2008). Future 
studies could utilize buffers that were formulated with a full amino acid profile similar to sow 
milk. 
 
5.7. Conclusion. 
       In isolated small intestinal segments, the delivery of lysyl-lysine with arginine resulted in 
greater arginine uptake and higher mucosal protein synthesis compared to arginine alone. The 
enhanced arginine uptake with lysyl-lysine may have been due to the trans-stimulation of b0, + 
antiporter that facilitated greater arginine uptake into enterocytes. Arginine is known to increase 
mucosal protein synthesis via the stimulation of the mTOR pathway (Bauchart-Thevret et al., 
2010), which is involved in cellular growth and protein synthesis; activation of the pathway occurs 
via phosphorylation of mTOR downstream targets P70S6K and 4E-BP1. Arginine is not the only 
amino acid that stimulates the mTOR pathway; relevant to this study, a recent study suggested that 
the dipeptide lysyl-lysine may also have a role in the mTOR pathway activation which may explain 
some of our findings in this study (Yin et al., 2016).  In the current study, when piglets were pre-
exposed to the mTOR pathway inhibitor, rapamycin, prior to the perfusion studies, mucosal protein 
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synthesis was inhibited by greater than 60%, and was not different amongst treatments. Moreover, 
rapamycin treatment inhibited the phosphorylation of mTOR, interfering with its activation.  
 
In the swine industry, it is becoming a common practice to add free amino acids to the diet while 
decreasing the crude protein content. This practice is adopted to lower both the nitrogen excretion 
and ammonia released in the animal’s waste, which are considered an environmental hazard 
(Hayes et al., 2004). Also, it was reported that lowering the crude protein in piglet diets can lower 
post-weaning diarrhea (Heo et al., 2008). However, the addition of free amino acids to the diet 
may affect the uptake of other amino acids which may have a negative consequence on piglet 
growth or recovery. As such, it may be more beneficial to add peptides to the diet with free amino 
acids to maximize the uptake by the small intestine, especially during stressful events. 
 
In situations of intestinal injury in neonates, such as weaning, infection, or following IV feeding, 
the small intestinal capacity for transporting free amino acids may be compromised; however, it 
may not be the case for peptides. As a result, supplying dietary amino acids as a combination of 
peptides and free amino acids may enhance uptake by the mucosa, which assists in improving GI 
recovery and overall performance. The results of the current study contribute information towards 
the design of an optimal diet which enhances amino acid absorption by the small intestine during 
stressful events and ultimately may contribute to optimizing growth. 
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